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1. CHAPTER 1: Introduction 
1.1. Early Detection of Ovarian Cancer 
1.1.1. Ovarian Cancer Subtypes, Stages, and Survival 
Ovarian cancer is the fifth leading cause of cancer-related deaths in women.  
Stage I ovarian cancer is defined by localized cancer in the ovaries or fallopian tubes, 
with only 15% of cases diagnosed at this stage [143].  The majority of cases are 
diagnosed at an advanced stage, defined as stage II when the tumor has spread to 
organs within the pelvis, stage III which involves the peritoneal surface of the pelvis or 
abdomen and surrounding lymph nodes, and stage IV with metastasis beyond the 
abdominal cavity [143].  Worldwide, the 5-year age-standardized net survival for stage I 
ovarian cancer is 80%, which decreases to 30% for advanced disease defined as stage 
II-IV for all subtypes [119].  Standard of care is primary optimal debulking surgery 
followed by platinum-based chemotherapy [9, 106].  The most significant prognostic 
factor is degree of residual disease following surgery [106].  The majority of patients 
with advanced disease experience a recurrence, of which 75% of recurrent cases 
cannot be cured [106].  The presence of chemoresistant stem-like cells contributes to 
tumor recurrence [96]. 
Ovarian cancer is classified as Type I and Type II, which represents 20% and 
80% of cases, respectively.  Type I ovarian cancer is less aggressive, low grade, is 
associated with ARIDA1, BRAF, PIK3CA, PTEN, and KRAS mutations, and is 
comprised of mucinous, clear cell, and endometrioid tumor subtypes.  Type II ovarian 
cancer has more aggressive, high grade tumors most commonly comprised of the 




between Type I and Type II tumors; Type I tumors originate as atypical benign 
conditions such as endometriosis which can implant on the ovary and transform, 
whereas Type II tumors originate in the fallopian tube as serous tubal intraepithelial 
carcinoma.  Type I ovarian cancer is largely diagnosed at stage I or II whereas Type II 
ovarian cancer is most often diagnosed at stage III or IV with decreased overall survival 
[101].  Seventy percent of all epithelial ovarian cancer cases are high-grade serous 
ovarian cancer (HGSOC); the present study evaluates a series of autoantibodies for use 
as diagnostic biomarkers in serum samples from patients with HGSOC [143].   
1.1.2. Early Detection in the General Population 
Three large randomized control trials have evaluated the effectiveness of 
screening for ovarian cancer in the general population.  In the Prostate, Lung, Colon, 
and Ovarian (PLCO) cancer trial, 68,557 women were followed [23].  Screening for 
ovarian cancer was performed with both Cancer Antigen 125 (CA125) and transvaginal 
ultrasound (TVUS).  Abnormal findings on either test prompted surgery, with no 
observed mortality benefit compared with the control arm with no screening.  CA125 is a 
glycoprotein that was identified as a biomarker for ovarian cancer and is elevated in 
80% of late stage cases and 50% of early stage cases [153].  It is also elevated in other 
benign gynecological conditions such as uterine fibroids, endometriosis, as well as other 
diseases such as cirrhosis and interstitial lung disease [4].  Alone, it is not an adequate 
biomarker due to insufficient sensitivity and specificity.  When measured at a single time 
point, CA125 has historically been considered elevated at a level >35 U/mL, and has 
been used to monitor recurrent disease.  The PLCO trial utilized a single measurement 




of the PLCO trial showed no difference in mortality for this screening method [23].  A 
randomized control study in Japan titled the Shizuoka Cohort Study of Ovarian Cancer 
Screening (SCSOCS) enrolled 41,688 women who were either screened annually with 
TVUS and CA125 interpreted at a single time point at the cutoff value of 35 U/mL [97].  
An increased proportion of stage I cases was observed, though this finding was not 
significant, and mortality was not reported [97]. 
 Improvements in early detection were observed in the UK Collaborative Trial of 
Ovarian Cancer Screening (UKCTOCS) due to improved screening methods by 
incorporation of the Risk of Ovarian Cancer Algorithm (ROCA).  ROCA detects 
increases in CA125 values over time relative to each patient’s baseline value, which 
improves specificity.  Additionally, imaging with TVUS is only initiated by increasing 
CA125 values, which greatly reduces false-positives. The UKCTOS study enrolled over 
200,000 patients, divided into a multi-modal screening arm using ROCA, a screening 
arm with yearly TVUS, and a non-screening arm [86].  Multi-modal screening with 
ROCA resulted in a stage shift with 36.1% detected at stages I-II [85].  Initial analysis at 
7 years suggests there may be a mortality benefit in the ROCA screening arm, and 
while follow-up long term analysis at 14 years remains to be reported, if trends observed 
at 7 years continue there is predicted to be an observed mortality decrease in the 
screening arm [86].   
1.1.3. Early Detection in High Risk Population 
Screening in increased-risk populations has the potential to be beneficial given a 
higher prevalence relative to the general population [75, 147, 166].  Those with a family 




ovarian cancer patients with BRCA1 and BRCA2 mutations that are frequently found in 
the germline of Type II HGSOC, and Lynch syndrome with mismatch repair gene 
mutations [43].  The clinical recommendation for women with known BRCA1 or BRCA2 
mutations or family history of ovarian cancer is prophylactic removal of the ovary and 
fallopian tubes.  Risk-reducing salpingo-oopherectomy (RRSO) reduces ovarian cancer 
incidence in high risk women [146].  Among patients with BRCA1/2 mutations, those 
who completed RRSO have reduced incidence of ovarian cancer and cancer-related 
mortality rates [112].  However, the decision to undergo surgery is complex, and there 
remains a population of women who choose not to undergo surgery.  In a study of 2,287 
women with increased familial risk of ovarian cancer, 40% of patients chose RRSO, 
while 60% chose ovarian cancer screening with the ROCA screening strategy [112].  
Risk of surgery, maintaining the option to have children, and both physiological and 
psychological side effects of removal of the ovary and fallopian tube stemming from 
surgical menopause including bone density loss and hormonal changes are factors that 
patients consider. [56, 112, 123].  An increased risk of multi-morbidity has been 
reported for patients undergoing bilateral salpingo-oopherectomy in a study comparing 
1,653 women retaining ovaries with 1,653 women at average risk for ovarian cancer 
who underwent surgery [144].  Women with the oophorectomy performed between the 
ages of 46-49 had a significantly increased risk of anxiety, depression, hyperlipidemia, 
diabetes, arthritis, and cancer.  Women who underwent surgery before the age of 46 
were also at a significantly increased risk for depression and hyperlipidemia, as well as 
for cardiac arrhythmias, coronary artery disease, arthritis, asthma, chronic obstructive 




 For women who decide to not have surgery, 3 prospective trials have recently 
examined the benefit of screening more frequently than once a year, and a stage shift 
was observed in cases detected.  In the UK Familial Ovarian Cancer Screening Study 
phase II trial, 4, 348 women at high-risk for ovarian cancer were screened for CA125 
every 4 months with yearly TVUS, which resulted in a significant stage shift in 
diagnosis.  Of the 19 total cases detected during the 5 years of screening, 10 were 
stage I-II [147].  Two prospective trials from the Cancer Genetics Network and the 
Gynecologic Oncology Group together screened 3, 962 women at high-risk for ovarian 
cancer with CA125 screening every 3 months, followed by TVUS upon increases in 
CA125 above the patient’s baseline.  In these trials, 3 of the 6 incident cases were 
stage I-II [166].  These trials also demonstrated compliance with frequent screening 
among high-risk women.  Additional biomarkers such as autoantibodies can be 
combined with CA125 to improve upon sensitivity in early detection.  For women at 
high-risk for ovarian cancer, an improved early detection method would provide the 
option of frequent screening for those who decline or delay prophylactic surgery. 
1.1.4. Strategies for Early Detection 
Although screening in high-risk women who decline surgery using the two-step 
ROCA as described above is an acceptable method for early detection in terms of 
sensitivity, specificity, and positive predictive value (PPV), there are limitations in both 
steps.  In the first step of CA125 detection, 20% of all cases will not express CA125, 
and 50% of early stage cases will not present with detectable levels of CA125 and are 
missed by ROCA [5, 164].  In the second step, TVUS has limitations of detecting early 




the first step by additional biomarkers to complement CA125 and novel imaging 
technologies can further develop early detection strategies.  For example, additional 
circulating antigens as well as circulating autoantibodies have been measured in 
samples without detectable CA125 in retrospective studies.  Novel biomarkers, imaging 
technology, and CA125 companion markers are outlined below. 
TVUS is the standard technique for imaging of the ovaries, however it is limited in 
visualization of the fimbriae of the fallopian tubes and is unable to detect small lesions 
[54].  Light-induced endogenous fluorescence can detect serous tubal intraepithelial 
carcinomas from surgically removed tissue with 73% sensitivity.  In vivo, falloposcopy 
has been proposed to detect serous tubal intraepithelial carcinoma with light-induced 
endogenous fluorescence [128].    
Circulating tumor cells (CTCs) can be isolated from blood by targeting epithelial 
antigens on the cell surface followed by sequencing. In a study measuring both CA125 
and CTCs in 153 serial serum samples from 51 patients with epithelial ovarian cancer, 
CTCs were demonstrated to be superior to CA125 detection with 90% sensitivity [208].  
CTCs detected 93% of stage I disease compared with CA125 which detected 64% of 
stage I samples.  However the ability to implement detection of CTCs into routine 
practice is limited.   
Cell-free circulating tumor DNA (ctDNA) can be amplified from blood samples 
and sequenced for mutations as well as analysis of DNA hypermethylation, copy 
number variation, and loss of heterozygosity [54]. CancerSEEK is a test combining 




majority of cases were advanced stage.  The limitation however is in the time frame 
required to process blood samples [114].  
miRNA can be detected in circulation within extracellular vesicles or bound to 
chaperone proteins, which make them stable analytes.  Multiple panels of miRNA have 
been identified with high performance of sensitivities of 62.4%, 86%, 75% and 
specificities ranging from 92.9%, 83%, and 100%, respectively [53, 198, 209].  The 
complementation of these panels with CA125 is not yet known, however in limited cases 
it was shown that CA125 positivity was independent of miRNA panel positivity, 
suggesting that these two strategies could be combined for an enhanced test.   
Methods of detection using body fluids in proximity to the ovaries such as 
isolation of DNA from tampons as well as uterine lavage have been performed to detect 
TP53 mutations [54].  Endocervical brushings were analyzed from 245 patients with 
ovarian cancer using PapSEEK, a test which examines 18 mutations or aneuploidy, and 
resulted in 99% specificity relative to 714 healthy controls with 33% sensitivity for all 
ovarian cancer cases, as well as 34% sensitivity among early stage cases. When using 
intrauterine brushing, PapSEEK resulted in 100% specificity with 45% sensitivity for 51 
ovarian cancer patients relative to 125 healthy controls; this study did not measure 
CA125 [54].   
There have been extensive studies of additional circulating antigens to 
complement CA125, of which the antigen HE4 has been most promising.  The 
European Prospective Investigation into Cancer (EPIC) cohort study enrolled over 
200,000 women, of which 810 developed ovarian cancer [165].  CA125, CA72.4, 




markers performed better than CA125.  HE4 was the only marker to marginally increase 
sensitivity in combination with CA125 [165].  The advantage of H4 is the superior 
specificity to CA125 [74].  Evaluation of serum samples from the UKCTOCS study, the 
combination of HE4 and CA72.4 was able to detect 16% of CA125-negative cases, 
however they were not detected with additional lead-time relative to CA125 [164]. 
1.1.4.1. Autoantibody Biomarkers 
When the tumor is at a small size, there may be insufficient amount of circulating 
antigens to be detectable in serum or plasma.  Autoantibodies are attractive biomarkers 
as they can be detected from a simple blood test, and they are more stable than 
circulating antigens.  The long-term stability of autoantibodies in frozen serum allow for 
prospective-retrospective research in biomarker discovery and validation stages using 
banked serum samples.  Studies of autoantibody tests for ovarian cancer to 
complement CA125 measurements and TVUS are currently ongoing.  A detailed 
literature review revealed that eighty-five autoantigens have been evaluated for the 
early diagnosis of ovarian cancer with ongoing studies seeking an optimal panel [61, 
92].  Due to inter-tumor heterogeneity and variable immune responses, it will be 
necessary to combine markers with the sensitivities of individual autoantibodies ranging 
from 10-30% to create a panel of antigens with sufficient sensitivity. 
An autoantibody response can be detected from microscopic lesions that are 
undetectable with imaging.  For example, the antibody associated with paraneoplastic 
encephalitis, Ma2, has been detected in patients with pre-invasive, microscopic 
intratubular germ-cell neoplasm unclassified type (IGCNU) [118].  In a study of 6 




all 6 patients were found to have pre-invasive, microscopic IGCNU [118].  In this study 
we evaluated a set of antigens associated with paraneoplastic syndromes for their use 
in the detection of autoantibodies for the early detection of ovarian cancer.  In a 
prospective study of serum samples from the UKCTOCS study, autoantibodies to TP53 
were detected 8.1 months prior to elevated CA125 detection and 9.2 months prior to 
ROCA detection in 34 cases that were screen-positive with ROCA, and 22.9 moths prior 
to diagnosis of ovarian cancer in the 9 cases that were screen-negative with ROCA 
[194].  Autoantibodies to tumor antigens, produced at small tumor volumes, can be 
combined with serum screening of CA125 to improve sensitivity in early detection.   
1.2. Tumor Immunology 
 The immune response to a transformed cells has been described by Schreiber et 
al. as a multistep process named “cancer immuno-editing” [154].  This theory describes 
the complex interaction of the immune system components of the microenvironment 
during tumor development, and the subsequent selection of tumor cells which evade the 
immune response.  The three stages of immuno-editing are defined as elimination, 
equilibrium, and escape, and are critical components of tumor biology. 
1.2.1. Immunotherapy and Ovarian Cancer 
The immune response and tumor immune microenvironment influence tumor 
development and patient survival.  Ovarian cancer has been shown to be immunogenic, 
and trials are currently evaluating the potential for both immunotherapies targeting 
tumor antigens and checkpoint blockade strategies [90, 116, 131].  The immune 
microenvironment has reproducibly been associated with prognosis in ovarian cancer; 




lymphoid structures (TLSs) in the tumor periphery is associated with improved 
prognosis for lung, colorectal, breast, prostate, and ovarian cancer [72, 125].  TLSs in 
ovarian cancer are associated with local memory B cells at the tumor site, as well as 
increased levels of immunoglobulin (IgG) [72, 125].  The presence of B cells at TLS is 
associated with increased patient survival in ovarian cancer [72].  
Treatment strategies involving adoptive transfer of T cells have been developed 
for antigens associated with ovarian cancer, particularly NY-ESO-1.  Cancer-testis 
antigens (CTAs) are ideal targets for immunotherapy due to their restricted expression 
in healthy tissue and overexpression in the tumor.  The quantity of available T cells 
limits adoptive transfer therapy, whereas chimeric antigen receptor T (CAR-T) cells do 
not have this limitation.  Targets for CAR-T cell therapy include NY-ESO-1, MUC16, 
Mesothelin, HER2, and folate receptor-alpha [89, 192].   
NY-ESO-1 is also a target for cancer vaccines.  A group that is pioneering 
strategies for immunotherapy in ovarian cancer has developed NY-ESO-1 vaccines 
currently being evaluated in phase 3 trials.  Usage of DNA methylation inhibitors to 
epigenetically enhance expression of cancer testis antigens such as NY-ESO-1 and 
LAGE-1 in combination with NY-ESO-1 vaccine and chemotherapy resulted in 6/10 
patients with partial clinical response or disease stabilization [132, 190].  Response was 
associated with increased NY-ESO-1 autoantibodies and NY-ESO-1 specific T-cells.  
This group has also demonstrated an upregulation of immune checkpoint pathways 
when either PD-1, LAG-3, or CTLA-4 were blocked by genetic ablation or antibodies in 
a mouse model [81].  These studies indicate that combination of blockade strategies 




Other targets of local immune suppression in ovarian cancer include indole-
amine-2,3,-dioxygenase (IDO) and vascular endothelial growth factor (VEGF).  
Macrophages secrete VEGF.  IDO promotes T cell differentiation to T-regs.  One trial in 
ovarian cancer patients in remission is evaluating the combination of an IDO inhibitor 
with an NY-ESO-1 vaccine in effort to extend rates of remission [131].   
Anti-PD-1 and anti-PD-L1 therapies as single agents have not been successful in 
ovarian cancer.  However combination of PD-L1 and CTLA-4 showed improved 
outcome relative to either agent alone. CTLA-4 antibodies in combination with 
chemotherapy, radiotherapy, and PARP-inhibitors have shown improved efficacy, due 
to the enhanced immune response driven by presentation of tumor cell antigens during 
cell death.  In a phase I/II clinical trial, the overall response rate for recurrent ovarian 
cancer patients receiving the combination of Parp-inhibition and PD-1-inhibition was 
45% for ovarian cancer patients with BRCA1/2 mutations compared with 25% for overall 
patients with ovarian cancer [107]. 
Importantly, the success of immunotherapy has been seen primarily in recurrent 
ovarian cancer patients, as these treatment strategies are in early clinical trial stages.  
After several lines of chemotherapy, which is enrollment criteria for the majority of the 
trials, patients can have T cell exhaustion and emergence of an immunosuppressive 
tumor microenvironment.  There is rational hope that immunotherapy as a frontline 
treatment could provide optimal outcomes [90, 116].   
1.2.2. Normal B-Cell Development and Generation of Antibody Diversity 
B cell receptors undergo two mechanisms of somatic mutation, recombination of 




hypermutation in the peripheral immune system [82].  These mechanisms generate 
random combinations at a scale to match the enormous diversity of possible amino acid 
combinations encountered in the body.  Generation of autoantibodies, or antibodies 
against non-foreign self-antigens, occurs when there is a breakdown of central or 
peripheral tolerance mechanisms.  Tolerance to a particular antigen is defined by 
lymphocytes with receptors specific to the antigen that remain alive but not active.  
There are a series of checks against auto-reactive IgG, but despite these checks, 
healthy individuals can harbor low titers of antibody against self-antigens without 
escalation of the response to autoimmune symptoms. 
In the bone marrow, developing B cells generate unique receptors with 
recombination from three gene segments, called V(D)J recombination.  T cells also 
undergo V(D)J recombination in the thymus.  Up to half of the B cell receptors and T cell 
receptors that result from V(D)J recombination bind with self-antigen [64].  In the bone 
marrow, when an immature B cell binds with self antigen, recombination-activating gene 
1 and 2 (RAG1 and RAG2) maintain expression and continue to participate in V(D)J 
rearrangement in effort to edit the B cell receptor [64].  Should the B cell receptor 
remain reactive with native self-antigen, the cell will be removed via clonal deletion.  
Cell death is mediated by decreased expression of the B-cell-activating factor receptor, 
which binds the growth factor B-cell-activating factor (BAFF), as well as increased 
expression of the pro-apoptotic factor BIM [64]. 
T cell receptors recognize linear peptide fragments that are presented on MHC 
molecules.  In the thymus, T cell receptors that weakly bind MHC with self-peptide 




and RAG2 genes are no longer expressed, whereas those that bind self-peptide too 
tightly activate cell death [64].  Genetic susceptibility to autoimmune diseases can be 
due to mutations in MHC molecules resulting in defective MHC binding to peptide and 
therefore ineffective deletion of self-reactive T cell receptors.  The autoimmune 
regulator protein, or AIRE, is a transcription factor responsible for expressing proteins 
that are organ-specific to present to developing T cells.  Genetic defects in AIRE can 
also result in autoimmunity, a prominent example being decreased expression of insulin 
in the thymus due to specific AIRE variants resulting in autoimmune diabetes [64].  
The second mechanism that generates B cell receptor diversity is somatic 
hypermutation of the B cell receptor, which occurs in germinal center follicles in the 
peripheral lymphoid tissues [64, 82].  During this process, antibodies are edited to 
increase the affinity for antigen binding, which is called affinity maturation.  At this stage 
B-cells differentiate to antibody-producing plasma cells and memory B cells.  
Furthermore, antibodies can undergo class switch recombination in which the of the 
heavy chain switches from IgM to IgA, IgH, IgE, IgD, and IgG with different effector 
functions [82].  Loss of immune tolerance can occur at multiple stages of B and T cell 
development. 
1.2.3. Development of an Autoimmune Response 
Both genetic and environmental factors contribute to the breakdown of central or 
peripheral tolerance and the development of autoimmune conditions.  Multiple genes 
associated with antigen processing or immunoregulatory mechanisms are involved in 
genetic susceptibility to autoimmune disease.  In patients with autoimmune disease, 




that are epigenetically deregulated or harbor mutations.  Variants in HLA genes that are 
involved in antigen processing and presentation via the MHC complex account for half 
of the known genetic risk loci for autoimmune diseases [156]. 
In addition to MHC alleles associated with inefficient epitope binding, it has also 
been theorized that epitope conformation can reduce or enhance the interaction with 
MHC.  Antigens that are intrinsically disordered have reduced affinity to MHC.  In 
particular, nuclear antigens have been characterized as having disordered epitope 
fragments, which is suggested to affect binding to MHC and may contribute to their 
escape from deletion in draining lymph nodes [24, 139].  These structural characteristics 
partially explain the overlap of those autoantibodies to nuclear complex proteins, DNA 
binding proteins and RNA binding proteins detected in autoimmune conditions and in 
cancer, where immune regulation is disrupted. DNA-binding proteins and dsDNA and 
ssDNA when bound to antibodies can also form immune complexes that can trigger 
stimulatory receptors.  Additionally, the protein structure can contribute to the propensity 
of certain antigens to become recognized as non-self proteins.  This includes regions 
prone to cleavage by Granzyme B, caspases, or cathepsins, which can expose 
otherwise hidden epitopes [16].  
Environmental factors include both the creation of an inflammatory and immuno-
stimulatory microenvironment with cytokines and activating signals, as well as exposure 
of cryptic epitopes via toxins or apoptosis.  Bacteria or virus can contain epitopes that 
are shared with self-antigens, and trigger an immune response against self-antigens 





1.2.4. Tumor Associated Antigens  
There are several conditions that can generate an antibody or immune response 
to a tumor.  This includes a breakdown of immune tolerance including genetic defects in 
antigen processing and presentation or down regulation of regulatory mechanisms, 
antigen overexpression or expression of an organ-specific antigen, changes in protein 
structure resulting from mutations and post-translational modifications, and cell death 
through tissue injury causing exposure of intracellular antigens [13]. 
 CTAs are a highly immunogenic class of tumor-associated antigens, with 
expression often restricted to germ cells of the testis at various stages of differentiation 
[59].  Cancer stem cells express CTAs at higher levels compared with the bulk tumor 
population [110, 163, 196]; several CTAs have been shown to be involved in early 
stages of embryonic development.  There are a number of antibodies shared by 
autoimmune disease and cancer.  For example TP53 autoantibodies have been 
detected in systemic sclerosis and systemic lupus erythematosus, and autoantibodies to 
c-myc have been detected in systemic lupus erythematosus and dermatomyositis as 
well as several tumor types [15].   
Normal expression of onconeuronal antigens is restricted to the brain and therefore 
expression of these antigens by a tumor can trigger an immune response; unregulated 
autoimmunity in this context results in a paraneoplastic neurological syndrome.   
1.3. Paraneoplastic Syndromes 
Paraneoplastic syndromes are a form of autoimmunity driven by antigen expression 
by the tumor, which directly demonstrates the anti-tumor immune response.  




response targets tumor antigens that are also expressed by neuronal or muscle cells.  
These syndromes are diagnosed before detection of the tumor in 70% of cases [66].  In 
cases where tumor antigens are shared with neuronal cells, referred to as onconeuronal 
antigens, patients have symptoms affecting the central nervous system.  When the 
antigen is shared with antigens in muscle cells or at the neuro-muscular junction, 
patients have symptoms affecting the peripheral nervous system.  The antibodies 
associated with these syndromes are more specific for the tumor type than for the 
resulting syndrome.  
Interestingly, paraneoplastic syndromes can result in spontaneous regression of 
the tumor, and immunological symptoms can resolve upon surgical removal of the 
tumor.  Return of paraneoplastic syndrome symptoms can indicate recurrence of the 
tumor.  Although paraneoplastic syndromes are rare, paraneoplastic autoantibodies 
have been reported in patients with lung, breast and ovarian cancer without a 
paraneoplastic syndrome.  For example, 16-25% of SCLC patients without a 
paraneoplastic syndrome were found to have autoantibodies to the paraneoplastic 
antigen HuD [93].   
 Paraneoplastic syndromes are categorized by neurologists into classical and 
non-classical syndromes, as described in Table 1.1 and Table 1.2 [67].  These 
definitions guide diagnosis of a definite paraneoplastic syndrome as being caused by an 
underlying tumor.  In addition to the following criteria, other known causes of 
neurological syndromes must be excluded to diagnose a definite paraneoplastic 
syndrome.  Classical paraneoplastic syndromes are highly associated with cancer, and 




diagnostic tests is undertaken immediately.  Classical syndromes with diagnosis of 
tumor within five years of presentation of symptoms with or without paraneoplastic 
antibodies are considered definite paraneoplastic syndromes.  Non-classical syndromes 
are less often caused by an underlying tumor and therefore to be categorized as 
paraneoplastic in origin, the syndrome should be accompanied by presence of 
paraneoplastic antibodies and tumor diagnosis within five years of presentation of 
symptoms.  Non-classical syndromes without presence of paraneoplastic antibodies 
that resolve upon treatment of tumor may also be considered definite paraneoplastic 
syndromes.  Diagnosis of a classical or non-classical syndrome with no tumor detection 
but with presence of well-characterized paraneoplastic antibodies can be considered 
definite paraneoplastic syndrome; these cases may represent an effective 
immunological tumor clearance [67]. 
1.3.1. Tumors Associated with Paraneoplastic Syndromes  
The main tumor types associated with paraneoplastic syndromes are small cell 
lung cancer, thymoma, breast, and ovarian cancer.  SCLC is the tumor type most 
frequently detected in patients with paraneoplastic syndromes.  The syndromes 
associated with SCLC are encephalomyelitis, cerebellar degeneration, opsoclonus-
myoclonus, sensory neuropathy, Lambert-Eaton myasthenic syndrome, and 
polymyositis as outlined in Table 1.1.  The paraneoplastic autoantibodies associated 
with SCLC are well characterized and can therefore be detected in 90% of SCLC case 
with paraneoplastic neurological syndromes [65].  In a prospective study which included 
n=240 SLCC cases without a paraneoplastic syndrome, 28.8% had detectable SOX2, 




a paraneoplastic neurological syndrome in the study, 87.5% were positive for at least 
one those three paraneoplastic autoantibodies.  
Thymoma is the second most common malignancy associated with 
paraneoplastic syndromes.  It has been reported that 30-47% of all patients with thymic 
epithelial tumors, predominantly thymoma, develop the paraneoplastic syndrome 
myasthenia gravis.  Myasthenia gravis is the result of autoantibody interference in the 
neuromuscular junction on skeletal muscle cells, which targets the acetylcholine 
receptor (AChR) in 85% of cases.  Autoantibodies against striated muscle antigens are 
detected in the majority of patients with thymoma and myasthenia gravis.   
Breast and ovarian cancer are associated with paraneoplastic cerebellar 
degeneration with majority of the cases reporting with anti-Yo autoantibodies.  Yo 
autoantibodies target both CDR2 (cerebellar degeneration related protein 2), also called 
PCA-1 (purkinje cell antibody 1), and CDR2L (cerebellar degeneration related protein 2-
like), which shares 50% homology to CDR2 [52].  It has recently been reported that 
CDR2L is the main target in paraneoplastic cerebellar degeneration, though Yo 
autoantibodies can be detected with both antigens [52].  Benign teratoma, a non-
epithelial ovarian germ cell cancer, is the tumor type most commonly associated with 
anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis, with reported 90% of 
tumor-associated anti-NMDAR encephalitis cases having ovarian teratoma [32, 83, 
202]. 
1.3.2. Etiology of Paraneoplastic Syndromes 
The development of a paraneoplastic syndrome is a result of autoimmunity; 





Table 1.1: Classical Paraneoplastic Neurological Syndromes. 
 
Classical Neurological 
Syndrome PNS in association with Cancer and Onconeural Antibodies References 
   Syndromes of Central 
Nervous System 
  Encephalomyelitis Esophageal small cell carcinoma (anti-Hu), SCLC (anti-Amphiphysin) [70, 161] 
Limbic encephalitis SCLC, breast  (anti-Hu, anti-ANNA-3); Testicular cancer (anti-Ma2) [71, 105] 
Subacute cerebellar 
degeneration 
Gynecological and breast cancer (anti-Yo, anti-Ri); Lung (anti-Hu); 
Hodgkin’s lymphoma (anti-Tr and anti-mGluR1); SCLC (anti-Zic4, 
anti-ANNA-3) [105, 158] 
Opsoclonus-myoclonus 
Lung cancer (anti-Ri, anti-Hu, anti-Amphiphysin, anti-P/Q-type 
Voltage-gated calcium channel (VGCC), breast and ovarian cancer 
(anti-Ri, anti-Yo), testicular cancer (anti-Ma-2) 
[14, 19, 77, 
126] 
   Syndromes of 
Peripheral Nervous 
System 
  Subacute sensory 
neuropathy SCLC (anti-Hu, anti-CV2(CRMP5), anti-Amphiphysin, anti-Yo) [8, 47] 
Chronic 
gastrointestinal 
pseudo-obstruction Thymoma (anti-Voltage gated potassium channel (VGKC)) [184] 
   Syndromes of 
Neuromuscular 
Junction and Muscle 
  Lambert-Eaton 
myasthenic syndrome 





Polymyositis Lung, ovarian and breast adenocarcinoma (anti-Jo-1, anti-Mi-2) [26, 203] 
    
 
 

















dneuronal or muscle tissues, breaking immune tolerance and resulting in 
Table 1.2: Non-classical Paraneoplastic Neurological Syndromes. 
Non-classical 
Neurological 
Syndrome PNS in association with Cancer and Onconeural Antibodies References 
Syndromes of Central 
Nervous System 
  Brainstem encephalitis Lung carcinoma (anti-Ri, anti-Hu) [19, 122] 
Optic neuritis caused 
by Neuromyelitis 
optica Lung adenocarcinoma (anti-Aquaporin-4) [183] 
Cancer-associated 
retinopathy Lung cancer (anti-recoverin) [140] 
Melanoma-associated 
retinopathy Melanoma (autoantibodies against rod bipolar cells) [170] 
Stiff person syndrome Breast cancer, thymoma, and colon cancer (anti-Amphiphysin) [170] 
Necrotizing 
myelopathy Leukemia  (No reports on well characterized onconeural antibodies) [63] 
Motor neuron diseases Thymoma (anti-CV2(CRMP5)) [182] 
   Syndromes of 
Peripheral Nervous 
System 
  Acute sensorimotor 
neuropathy SCLC (anti-Hu) [151] 
Guillain-Barre 
syndrome Lung adenocarcinoma (anti-CASPR2) [176] 
Brachial neuritis 




neuropathies SCLC (anti-Hu) [113] 
Neuropathy and 
paraproteinaemia 
Multiple Myeloma, non-Hodgkin’s lymphoma, chronic leukemias 
(anti-MAG) [145] 
Neuropathy with 
vasculitis Gastric cancer (antinuclear cytoplasmic antibody (ANCA)) [36] 
Autonomic 
neuropathies SCLC (anti-collapsin response mediator protein 5 (CRMP-5)) [127] 
Acute 
pandysautonomia NSCLC (No reports on well characterized onconeural antibodies) [178] 
   Syndromes of 
Neuromuscular 
Junction and Muscle 
  Myasthenia gravis Thymoma (anti-acetylcholine receptor (AChR)) [206] 
Acquired 
neuromyotonia Thymoma (anti-VGKC) [58] 
Acute necrotizing 
myopathy Merkel cell carcinoma (MCC) (anti-Hu) [78] 
    






neuronal or muscle tissues, breaking immune tolerance and resulting in autoimmune 
tissue damage. The occurrence of antibodies in serum and cerebrospinal fluid (CSF) 
that recognize the antigens shared by neurons and tumor cells has been reported, 
however only a fraction of tumor-bearing patients with elevated titers of paraneoplastic 
autoantibodies will develop a neurological syndrome. Cross-reactivity of tumor and 
nervous tissue alone is insufficient to cause a paraneoplastic neurological syndrome 
and other factors are necessary including enhanced cytokine production, increased 
MHC-1 expression, and infiltration of CD8+ T-cells to the tissue site [44].  Like other 
autoimmune diseases, development of paraneoplastic neurological syndrome is due to 
a combination of environmental and genetic factors.  There have been associations with 
HLA haplotypes with increases susceptibility to paraneoplastic syndromes [162, 201].  
Presumably, in patients with insufficient binding of epitopes to MHC proteins, there can 
be errors in clearance and these epitopes can be allowed to persist undetected as a 
self-antigen.  
Somatic mutations in target antigens for paraneoplastic cerebellar degeneration, 
CDR2 and CDR2L have been reported.  Of 26 ovarian cancer cases with antibody-
positive cerebellar degeneration, 65% of cases had at least one somatic mutation, and 
59% also had CDR2L gene amplification [167].  All 26 cases had either gene 
amplification or somatic mutation in the CDR2/CDR2L genes.  Additionally, missense 
mutations were predicted to have enhanced binding to MHC I.  None of the 116 control 
samples from patients with ovarian cancer without paraneoplastic cerebellar 





1.3.3. Autoantibodies Associated with Paraneoplastic Syndromes 
1.3.3.1. Intracellular Antigens 
Intracellular antigens include anti-nuclear antibodies, such as DNA and RNA 
binding proteins, and cytoplasmic antigens including tRNA synthetase antibodies, and 
syndrome-specific antibodies.  The symptoms of paraneoplastic syndromes involving 
intracellular antigens are primarily the result of T-cell mediated destruction of healthy 
tissue.  This is evidenced by infiltration of CD8+ T cells in autopsied and biopsied tissue.  
In patients with paraneoplastic cerebellar degeneration, paraneoplastic Yo antigen 
specific cytotoxic T-cells have been detected in patient blood samples [2].  Symptoms of 
paraneoplastic syndromes that target intracellular antigens including onconeural 
antigens can be irreversible due to T-cell mediated death of neurons. 
 Studies have also shown antibody-uptake in rat brain neurons with functional 
consequences, suggesting possible additional methods of neuronal death in addition to 
cytotoxic T-cell targeted attack.  Intracellular uptake and demonstrated binding of anti-
Yo antibodies resulted in disruption of calcium homeostasis in rat cerebellar slice culture 
[155]. Greenlee et al. has reported cellular uptake of both anti-Yo and anti-Hu patient 
antibodies in rat slice culture [68, 69]. 
1.3.3.2. Extracellular Antigens 
In paraneoplastic syndromes that target membrane bound proteins, the 
antibodies can be directly pathogenic.  Antibodies target various neuronal cell surface 
channels and receptors including: voltage-gated potassium channel-complex, ionotropic 
glutamate receptors (iGluRs), metabotropic glutamate receptors (mGluRs), gamma-




targeting the neuromuscular junction include voltage-gated calcium channels, muscle 
AChR, and ganglionic AChR, as outlined in Tables 1.1 and 1.2 [83].  
1.3.3.3. Treatment 
Autoantibodies targeting antigens located extracellularly on the cell membrane 
can directly cause symptoms.  Dalmau et al. reported that in paraneoplastic encephalitis 
associated with NMDAR antibodies, a rapid correction of symptoms after surgery for 
ovarian teratoma was observed [45].  The target antigens include extracellular 
receptors, and in most cases the antibodies are directly pathogenic.  Therefore 
removing or diluting circulating IgG provides benefit to these patients. Paraneoplastic 
syndromes that target extracellular antigens are easier to manage with treatment 
options such as intravenous immunoglobulin (IVIg) and plasma exchange therapy (PE). 
IVIg consists of a blood-derived product collected from humans. The mechanisms of 
action are not completely understood, but IVIg is involved in the inhibition of B cells and 
production of autoantibodies as well as saturation of FcRn receptor, which is involved in 
recycling of IgG through protection from lysosomal degradation [17, 168]. IVIgs have 
been used in the treatment of some autoimmune diseases like Guillain-Barré. 
Syndrome, chronic demyelinating polyneuropathy, and systemic lupus erythematosus 
[168]. PE and immunoadsorption (IA) are procedures that help to remove circulating 
antibodies. PE removes antibodies in a non-specific manner, whereas IA removes 
antibodies with a high specificity due to the presence of an adsorber (commonly 
tryptophan). A retrospective study revealed that in a study population of 31 patients who 
had autoimmune encephalitis, 22/31 had autoantibodies against N-methyl-d-aspartate 




treatment with PE and IA showed an improvement in modified ranking score in 67% of 
the patient population [51]. 
In contrast, the evaluation of IVIg treatment was reported by Uchuya et al. in a 
retrospective study including 22 patients with anti-Yo and anti-Hu PEM and sensory 
neuropathy, both intracellular targets. Stabilization was observed in 10% of patients who 
received IVIg at a dose of 0.5 g/kg/day for 5 days, and was carried on for 3 months 
[177].  Due to the primary involvement of CD8+ T cells and permanent loss of neuronal 
cells, paraneoplastic syndromes targeting intracellular antigens such as cerebellar 
degeneration have poor prognosis and can often be fatal.  Treatment with IVIg or PE is 
of little benefit for cases targeting intracellular antigens.  Instead, immunosuppression 
via steroids or depletion of lymphoid populations with immunotherapeutics such as 
Rituximab can alleviate some symptoms.  
1.3.4.   Immunotherapy and Neurological Adverse Events 
1.3.4.1. Mouse Models 
The presence of autoantibodies alone is not sufficient to cause paraneoplastic 
syndromes.  This is reflected by the fact that the frequency of patients with cancer 
positive for paraneoplastic autoantibodies is higher than the frequency of patients with 
cancer who develop paraneoplastic syndromes as well as directly demonstrated by 
mouse models where administration of autoantibodies is insufficient to cause disease.  
A model involving CTLA4, however, was shown to invoke paraneoplastic syndrome 
[200].  In this model, breast cancer cells expressing influenza hemagglutinin antigen 
(HA) were implanted into balb/c mice.  The mice expressed HA with cre recombinase in 




receptors were injected intravenously, and the tumor growth was decreased relative to 
controls.  The mice however did not express any neurological symptoms.  When this 
syngeneic mouse model was treated with anti-CTLA4, the anti-tumor response was 
increased and in addition the mice displayed evidence of cerebellar degeneration both 
behaviorally and with Purkinje cell loss with inflammation of the cerebellum.  When mice 
with HA-expressing tumor cells but without HA expressing purkinje cells were injected 
with anti-hemagglutinin CD4+ and CD8+ T cells, treatment with anti-CTLA4 had 
comparable affect on tumor regression but did not result in any neurological symptoms.  
Similarly, administration of anti-PDL1 antibody in a mouse model for autoimmune 
encephalomyelitis exacerbated the neurological symptoms.  This mouse model for 
autoimmune encephalomyelitis is initiated by immunization to myelin oligodendroctye 
glycoprotein peptide [152].   Increased infiltration of lymphocytes to the CNS as well as 
increased antigen-specific T cell expansion and cytokine production were observed 
after PD-1 blockade [152]. 
Mouse models with antibodies that target cell surface antigens however can 
induce neurologic symptoms without inhibition of immune checkpoints.  Autoantibodies 
targeting mGluR from patients with paraneoplastic cerebellar degeneration were 
injected into mice intrathecally and resulted in severe cerebellar ataxia in mice, which 
was reversible with removal of the autoantibodies [205].   
1.3.4.2. Case Reports 
Paraneoplastic syndromes are a form of autoimmunity driven by antigen 
expression on the tumor, and they are a demonstration of the mechanisms of tumor 




not caused by a paraneoplastic syndrome.  Neurotoxicity associated with CAR T cell 
therapies includes CAR T cell- related encephalopathy syndrome and cytokine-release 
syndrome [129].   Therapies targeting immune checkpoints can result in immune-related 
adverse events (irAEs), which includes paraneoplastic syndromes.  Use of checkpoint 
inhibitors has resulted in paraneoplastic syndromes to arise in tumor types not 
otherwise associated with paraneoplastic syndromes, such as melanoma [205].  
Dermatomyositis was diagnosed in a woman with metastatic melanoma who was 
treated with CTLA-4 inhibitor ipilimumab.  The dermatomyositis symptoms resolved 
when therapy was discontinued, and they returned when ipilimumab was again 
administered [159].  In another case report of metastatic melanoma, a patient was 
treated with both ipilimumab and nivolumab.  Within two weeks of treatment, the woman 
developed symptoms indicative of autoimmune encephalitis, and was treated with IVIG 
and methylprednisolone [188].  The patient was tested for presence of paraneoplastic 
antibodies, and NMDAR antibodies were detected in the cerebrospinal fluid.  After 
treatment with rituximab, the patient’s symptoms improved [188]. 
A phase 2 clinical trial measured correlation of paraneoplastic antibodies with 
neurotoxicity when SCLC patients were treated with the immuostimulatory agent 
ipilimumab, which is an anti-CTLA-4 antibody targeting T-regulatory cells [10].  Results 
indicated that presence of paraneoplastic syndrome associated autoantibodies at the 
start of treatment correlated with severe paraneoplastic neurotoxic effects [10].  In 
addition to early detection, assessment of paraneoplastic autoantibodies may provide 




identify patients at risk for developing neurologic irAEs prior to treatment with 
checkpoint inhibitor immunotherapies.   
1.3.5. Paraneoplastic Syndromes Associated with Ovarian Cancer 
The paraneoplastic syndromes most commonly associated with ovarian 
carcinoma include paraneoplastic cerebellar degeneration, dermatomyositis and 
polymyositis [202, 203]; women presenting with these syndromes are referred for 
evaluation of ovarian cancer.  Symptoms of cerebellar degeneration include ataxia, lack 
of balance, speech dysfunction, and nystagmus.  Antibodies associated with 
paraneoplastic cerebellar degeneration that have been detected in women with ovarian 
cancer include anti-Yo, anti-Ri, and anti-Amphiphysin [202].  Polymyositis is an 
inflammatory myopathy resulting in muscle weakness, in cases of dermatomyositis, skin 
rashes co-occur with muscle weakness.  Patients with these symdromes are at higher 
risk for malignancy, with detection of a tumor in 30% of dermatomyositis cases and in 
15% of polymyositis cases [157]; relevant antibodies include anti-Jo1, anti-mi2, and 
anti-SRP [105].  Paraneoplastic autoantibodies that have been reported in cases with 
ovarian cancer are listed in Table 1.3.  The presence of paraneoplastic autoantibodies 
is criteria for diagnosis of a paraneoplastic syndrome in patients with neurological 
symptoms, meaning the neurological syndrome is caused by the tumor-initiated immune 
response.  However, paraneoplastic autoantibodies can also be detected in serum from 
patients with a tumor that do not present with neurological symptoms.  Therefore, 
detection of autoantibodies associated with paraneoplastic syndromes is an approach to 





Table 1.3:  PNS Autoantibodies Reported in Ovarian Cancer Cases. 
 
 
PNS in association with 
ovarian cancer 
 
Onconeural antibodies targeting 








Yo antibody or Purkinje cell cytoplasmic 













Carbonic anhydrase-related protein VIII 






Degeneration Creatine kinase B (CKB) antibodies NM_001823 [174] 
Paraneoplastic 
encephalomyeloneuropathy 




Encephalomyelitis Amphiphysin antibodies NM_001635 [199] 
Myositis Jo-1 autoantibodies, Histidyl-tRNA synthetase  (HARS)  AAX99363.1 [203] 
Myositis SRP-19 autoantibodies U51920.1 [73] 
Myositis, Myasthenia gravis Cortactin antibodies BC008799.2 [18] 
Dermatomyositis TIF1-γ (TRIM33) autoantibodies or anti-p155/140 NG_023287.1 [117] 
Dermatomyositis NXP-2 autoantibodies, or anti-MJ antibodies NM_015358.2 [84] 
Paraneoplastic Cerebellar 
Degeneration Yo antibody (CDR2L) NM_014603 [52] 
Idiopathic inflammatory 
myopathy, Sjogren’s syndrome 
and SLE 
Ro52 autoantibodies (TRIM21) NM_003141.3 [55, 149] 
Antiphospholipid antibody 
syndrome Phospholipid antibodies N/A [148] 
 
 
Table 1.3:  Paraneoplastic Autoantibodies Reported in Ovarian Cancer.  Table adapted 
from “Chatterjee M, Hurley LC, Tainsky MA. Paraneoplastic antigens as biomarkers for 

















Dermatomyositis and less commonly polymyositis are paraneoplastic syndromes 
that can precede the diagnosis of ovarian cancer.  The pathogenesis of polymyositis is 
mediated by cytotoxic T-cells, as evidenced by an infiltration of CD8 + T-cells in the 
muscle of myositis patients, which are recruited by local inflammation [25].  Additional 
symptoms in dermatomyositis are caused by immune-complexes binding to endothelial 
cells, activating the complement system and resulting in cell lysis and capillary 
destruction through the membrane attack complex [25].  
In paraneoplastic myositis, the target of immune attack is regenerating muscle 
tissue, where in times of injury and muscle repair there is exposure of intracellular 
antigens.  It has been shown that the paraneoplastic antigens HARS and mi-2 are found 
at high levels in developing muscle and myositis muscle, compared with low levels in 
healthy muscle [26].  In vitro studies demonstrated that HARS and mi-2 were expressed 
at high levels in myoblasts, and decreased as these cells differentiated to form 
myotubes [26].  In addition to analysis of antigens in myositis muscle tissue and human 
myotube cell culture, increased expression of myositis-associated antigens was 
observed in regenerating mouse muscle [138].  Additionally, HARS expression was 
found to be higher in the muscle of newborn rats compared with adult tissue [204].  
1.3.6.1. Myositis-Associated and Myositis-Specific Autoantibodies 
The Jo-1 autoantibody that recognizes the Histidyl-tRNA synthetase (HARS) is 
an antibody specific to myositis [203]. Chatterjee et al. have independently identified an 
epitope of the anti-Jo-1 target, HARS, through a phage-display screening of serum IgGs 




antigens, had the ability to predict ovarian cancer recurrence 9 months prior to the 
standard clinical recurrence criteria including CA125 [27].   
Other autoantibodies found in the serum of myositis patients include anti-Ro52, 
anti-PL-7, anti-PL-12, anti-Mi-2, anti-PM-Scl75, anti-PM-Scl100, and anti-Ku [41].  
Patients with inflammatory myopathies that are positive for anti-Jo-1 are often positive 
for anti-Ro52 antibodies, which target the antigen TRIM21. In one study examining the 
sera of 112 patients with inflammatory myopathies, 21% of patients were anti-Jo-1 
positive, 20% of patients were anti-Ro52 positive, and 58% of those anti-Jo-1 positive 
patients were also positive for anti-Ro52 [149].  In a study of 89 anti-Jo-1 positive 
patients with anti-synthetase syndromes including polymyositis and dermatomyositis, 36 
were also Ro52 positive. It was also found that when Jo-1 and Ro52 antibodies co-
occurred, the risk of malignancy was increased, with reported cases of colon, breast, 
ovarian, and esophageal cancer [115].  Therefore, these two antigens together on a 
panel could increase cancer diagnostic specificity of an autoantibody classifier.  
Ishikawa et al. reported a study of screening of patients with connective tissue disease 
including myositis and dermatomyositis for the detection of autoantibodies that target 
nuclear matrix protein 2 (NXP-2). Out of 206 patients screened, 6 were positive for 
NXP-2. The study showed that 1 out of these 6 patients had dermatomyositis diagnosed 
at the same time as diagnosis of ovarian cancer. The patient was negative for 
antibodies to transcription intermediary factor-1 gamma (Tif1-gamma) but positive for 
antibodies to NXP-2 [84].  In another study of patients with inflammatory myopathies 
screened against an inflammatory myopathy immunoprofile test, 11/80 patients tested 




had a cancer. Out of these 5 cancer cases with positive inflammatory myopathy 
immunoprofiles, 1 of the cases was a woman with ovarian cancer who tested positive 
for Tif1-gamma [117].  Fiorentino et al. reported that in a cohort of 111 patients at the 
Stanford University Dermatology Clinic and a cohort of 102 patients at the Johns 
Hopkins Myositis Center, positivity to either NXP-2 or Tif1-gamma was present in 83% 
of patients with Cancer-Associated Dermatomyositis [57].  Suzuki et al. reported the 
presence of anti-SRP54 antibodies in 100 patients who had an inflammatory myopathy, 
5 of whom had a malignancy, including 1 ovarian cancer [169].  In these studies we 
investigated a panel of autoantibodies associated with myositis for potential ovarian 
cancer biomarkers. 
1.3.7. Paraneoplastic Cerebellar Degeneration 
In ovarian cancer-associated cerebellar degeneration, cytotoxic T-cell attack is 
targeted to the Purkinje cells of the cerebellum. Destruction of Purkinje cells affects 
speech and motility, and often results in patient death.  Case reports have 
demonstrated otherwise undetectable microscopic ovarian cancer in patients with Yo-
positive cerebellar degeneration, which was discovered upon laparotomy and 
pathological analysis of resected tissue, prompted by diagnosis of cerebellar 
degeneration [62, 135] 
1.3.7.1. Autoantibodies Associated with Cerebellar Degeneration 
Yo antibody is also known as Purkinje cell cytoplasmic antibody type 1 (PCA-1), 
is targeted against CDR2 antigen that with limited normal protein expression in the brain 
and testes, as well as overexpression in ovarian cancer with or without cerebellar 




homology to CDR2 and its expression has been observed in both ovarian tissue and 
cerebellar Purkinje cells. Eichler et al. has reported that in a study population 
comprising patients with ovarian cancer, breast cancer and paraneoplastic neurological 
syndrome patients with Yo-positive antibodies, those patients who had paraneoplastic 
cerebellar degeneration, harbored antibodies directed against both CDR2 and CDR2L 
[52].  Darnell et al. reported that the tumor-specific expression of CDR2 in neurologically 
normal patients with ovarian cancer. In this study, tumor specimen lysates were 
prepared from 20 ovarian cancer patients were probed with sera obtained from 
paraneoplastic cerebellar degeneration patients on western blot and 13/20 tumor 
lysates showed the expression of CDR2 (target of anti-Yo antibodies) both in cerebellar 
neuronal tissue and ovarian tumors [46].  Expression of CDR2 was also observed in 
ovarian cancer patients who had no clinical manifestation of paraneoplastic cerebellar 
degeneration or circulating anti-Yo antibodies [46]. Therefore, the expression of 
onconeural antigens and their association with their respective antibodies does not 
always associate with the appearance of paraneoplastic neurological syndrome [46].  
Monstad et al. determined the prevalence of Yo antibodies in a study population 
comprising 557 ovarian cancer patients and 253 breast cancer patients, few of which 
were associated with paraneoplastic neurological syndrome. The frequency of Yo 
antibody association with ovarian cancer was found to be 13/557 (2.3%), as opposed to 
4/253 (1.6%) patients with breast cancer. Only 2/13 ovarian cancer patients had 
paraneoplastic cerebellar degeneration prior to diagnosis of ovarian cancer [124].  For 
paraneoplastic autoantibodies to be clinically useful for ovarian cancer diagnostics, 




case study of a 60-year patient who initially had paraneoplastic cerebellar degeneration. 
After performing paraneoplastic antibody screening, only Zic4 antibody titer in serum 
was found to be elevated. CSF also showed presence of Zic-4 antibodies. Thoracic and 
abdominal CT scans revealed the presence of a tumor in the right ovary and diagnosis 
of ovarian adenocarcinoma was confirmed [95].  Hoftberger et al. reported the 
appearance of carbonic anhydrase-related protein VIII (CARP VIII) antibodies in 
association with paraneoplastic cerebellar degeneration at the time of ovarian 
adenocarcinoma tumor recurrence in a 69-year woman [79].  CARP VIII protein is 
expressed in the brain Purkinje cells, however strong expression of CARP VIII protein 
has been observed in lung cancer and has been linked to its higher proliferative and 
invasive properties that are essential for tumor growth and progression [1].  Lennon et 
al. investigated the frequency of anti-P/Q and N type calcium-channel antibodies in a 
study population of cancer patients. Of 70 small-cell lung, ovarian or breast carcinoma 
patients who were associated with a paraneoplastic encephalomyeloneuropathy, 2/19 
(5%) ovarian cancer patients were reported to harbor antibodies against P/Q-type and 
N-type calcium channels. The calcium channel antibodies were detected in human 
cerebellar and cerebral cortical tissues [104].  Antoine et al. reported the occurrence of 
Amphiphysin antibodies in ovarian cancer patients in a study comprised of 2800 
patients but only 5 were selected after pre-screening the sera for the presence of 
Amphiphysin antibodies. Among 5 patients, who were diagnosed with encephalomyelitis 
prior to ovarian cancer diagnosis, one was found to have circulating Amphiphysin 
antibodies [7].  A case report by Forgy et al. revealed that an ovarian cancer patient 




surgery despite the fact that her CT scan report, CA125 levels, and physical 
examinations indicated no recurrence of ovarian cancer, yet her levels of Yo antibodies 
in the serum and in the CSF were both > 320 U/ml (normal range is < 10 U/ml) [60]. 
1.3.8. Paraneoplastic Autoantibodies Previously Associated with Ovarian 
Cancer 
In addition to classical paraneoplastic autoantibodies associated with myositis or 
cerebellar degeneration, additional paraneoplastic autoantibodies have been reported in 
ovarian cancer primarily in case studies as summarized in Table 1.3.   
1.3.9. Sero-Negative Samples for Identification of Novel Paraneoplastic     
Antigens 
 Although paraneoplastic antibodies known to be associated with cancer have 
been studied in detail, the search for new paraneoplastic cancer associated 
autoantibodies is ongoing.  Novel antigens involved in central nervous system synaptic 
or neuronal surface autoantibody disorders have recently been identified at an 
approximate rate of two per year [103]. Two recent findings include antibodies to 
cortactin and creatine kinase brain type (CKB) [18, 174].  Cortactin was recently 
identified as a paraneoplastic antigen in two independent studies [18].  Following 
identification, both groups screened paraneoplastic sera against cortactin; one group 
detected cortactin antibodies in 20% of polymyositis patients using ELISA with western 
blot confirmation, while the other group identified cortactin antibodies in 19.7% of 
myasthenia gravis patients who were sero-negative for classic paraneoplastic antigens 
[18].  Myositis is a paraneoplastic syndrome closely linked with ovarian cancer. 




of tumor tissues as well as by immunohistochemical staining of cortactin on tumor 
histological sections, and its expression was associated with poor prognosis [108]. 
Another recently identified paraneoplastic antigen is creatine kinase brain type, CKB. In 
an effort to identify novel paraneoplastic antigens in patients with cerebellar 
degeneration that were sero-negative for classic paraneoplastic markers, 2D western 
blot of paraneoplastic antibody sero-negative sera followed by mass spectrometry 
identified CKB as a novel paraneoplastic cerebellar degeneration-associated antigen 
[174].  CKB serum antibody reactivity was demonstrated in the cytoplasm of mice 
Purkinje cells as well as urinary bladder cancer tissue samples. CKB was elevated in 
several cancers including stage 1 ovarian cancer patients and was demonstrated to 
contribute to cancer progression [108]. As more paraneoplastic antigens are 
discovered, the panel of antigens to use for diagnosis of ovarian cancer could be 
expanded. 
1.4. Paraneoplastic Antibodies for Early Detection 
1.4.1. Paraneoplastic Antibodies as Cancer Biomarkers 
As lung cancer is associated with paraneoplastic syndromes, an FDA-approved 
ELISA based test for smokers at risk for lung cancer, the EarlyCDT-Lung panel of 
antigens for the autoantibody detection of lung cancer, includes the paraneoplastic 
autoantigens HuD and SOX2. HuD and SOX2 are associated with limbic encephalitis, 
sensory neuronopathy and Lambert-Eaton myasthenic syndrome, and HuD is also 
associated with paraneoplastic encephalomyelitis and paraneoplastic cerebellar 




and SOX2 is 41%, and in an audit of its first 1,600 screenings in the clinic, 57% of test-
positive cases were early stage I or stage II NSCLC [87].  
Cui et al., reported a study on autoantibodies to the paraneoplastic antigen Ma2 
for the early detection of recurrence for small intestine neuroendocrine tumors (SI-
NETs). The study evaluated 124 serum samples obtained from patients diagnosed with 
SI-NETs on an ELISA platform with recombinant Ma2 protein, which resulted in high 
sensitivity and specificity as revealed by the ROC values between 0.734 and 0.816 [42].   
1.4.2. Panel of Autoantibodies for Early Detection    
It is well established that while individual autoantibodies have low frequency of 
positive titer among patient sera, a combination of autoantigens for detection of 
autoantibodies can greatly increase diagnostic sensitivity. Matt et al. developed a 
multiplex Luminex assay using six onconeuronal antigens, namely NOVA-1 (Ri 
antibodies), HuD, Ma2, CDR62 (Yo antibodies), CRMP-5 (CV2 antibodies), and 
Amphiphysin to immunoscreen 119 patients who had definite paraneoplastic syndrome.  
Their assay yielded a high sensitivity, such as 83% for Ri antigen, 91% for Ma2, 93% for 
HuD and 100% for Yo, CV2 and Amphiphysin.  Higher specificity was also obtained, like 
96% for CV2, 97% for HuD, Yo, Amphiphysin, 99% for Ma2 and 100% for Ri antigens 
[111].  In a review of 60 ovarian cancer biomarker publications, of the 27 studies 
involving TAA or autoantibody multi-analyte panels, it was demonstrated that improved 
sensitivity with a panel of markers can be achieved while maintaining specificity [160].  
Therefore a panel of multiple antigens should increase the sensitivity of antibody-based 
tumor diagnostics, and in the case of ovarian cancer, a panel including paraneoplastic 




or known BRCA1/2 mutations.  A panel of autoantibodies could be measured CA125; 
both the antigen and antibodies could be analyzed from a patient serum sample.  Other 
cancers, especially those associated with paraneoplastic syndromes such as breast, 
lung, pancreatic, colon, and lymphoma, could benefit from TAA combined with 
autoantibody detection.  
1.4.3. Methods of Detection of Autoantibodies 
 The evaluation of onconeural antibodies in ovarian cancer serum samples with or 
without paraneoplastic syndrome was used to generate a panel of paraneoplastic 
antigens to implement in screening on various clinical platforms.  Standard approaches 
for the detection of autoantibodies in patient serum are ELISA and western blot [13].  
Immunohistochemistry and cell-based fluorescence are also used in particular for 
intracellular onconeuronal antigens.  Rat and primate brain slices are commonly used 
for expression patterns of neuronal cell-surface antigens [179] .  Immunohistochemistry 
however is difficult to interpret and subject to user bias.  Immunocytochemistry is also 
used on cultured rat hippocampal neurons.  Cell-based assays using transformed cells 
such as HEK or HeLa cells overexpressing the target antigen can be incubated with 
patient serum and measured for staining [179].   
 More sensitive and rapid tests have recently been developed for autoantibody 
detection, including electrochemical, optical, and microfluidic approaches [191].  Optical 
approaches include surface plasmon resonance (SPR), localized surface plasmon 
resonance (LSPR), and surface enhanced Raman spectroscopy (SERS) [191].  
 For autoantibody discovery phases, mass spectrometry is a reliable method, 




cell lysates are separated on a 2D SDS PAGE gel, and spots specific to disease 
samples are analyzed by mass spectrometry. Serological analysis of recombinant cDNA 
expression libraries (SEREX) has historically been used for discovery of many tumor-
associated antigens, including NY-ESO-1 [13, 33].  Protein microarrays are an 
improvement from SEREX in that these arrays utilize purified recombinant protein, 
eliminating much of the background noise generated from using E. coli cell lysates in 
SEREX.  A prominent example of a human protein microarray is Nucleic Acid 
Programmable Protein Arrays (NAPPA) [13]. 
1.5. Hypothesis: Autoantibodies Associated with Paraneoplastic Syndromes 
are Candidate Biomarkers for Early Detection of Ovarian Cancer 
 As paraneoplastic antigens initiate autoimmune responses, these are highly 
immunogenic proteins expressed by the tumor.  While paraneoplastic syndromes are 
rare, autoantibodies associated with the syndromes are more common. In SCLC, 16-
25% of cases without a paraneoplastic syndrome had detectable anti-Hu antibodies, 
and 40% of SCLC cases without a neurological syndrome had a detectable levels of at 
least one paraneoplastic antibody from a panel of intracellular and cell surface antigens 
[65, 93].  Therefore, we evaluated a set of myositis associated and onconeuronal 
autoantigens for detection of autoantibodies in serum from ovarian cancer patients 
without a known paraneoplastic syndrome.  
The primary goal of this thesis is to identify candidate autoantibody biomarkers 
for early detection of ovarian cancer.  In addition to early detection, understanding the 
distribution of autoantibodies in patients without neurological symptoms may help to 




of immunotherapy neurologic irAEs.  Baseline levels of paraneoplastic autoantibodies 
could serve to identify patients that would be at risk for developing neurologic irAEs as 
























2. CHAPTER 2: Materials and Methods 
2.1. Collection of patient samples 
 Samples were obtained from patients at Karmanos Cancer Institute, St. John 
Hospital and Oakwood Hospital in Detroit, MI, and at the Mayo Clinic, Rochester, MN. 
Additional specimens were provided by the Cooperative Human Tissue Network 
(CHTN) and Gynecologic Oncology Group specimen banks.  All samples were collected 
prior to surgery or therapy.  Healthy control sera were collected as part of a large-scale 
community outreach project.   Blood was collected via venipuncture, centrifuged at 
2,500 rpm at 4°C, and the resulting serum stored at -80°C.   Protocols were approved 
by the Institutional Review Boards of Wayne State University and the individual 
hospitals.  Each patient provided written informed consent. 
 For the Validation I and Validation II studies, the early and late stage HGSOC 
group is comprised of females age 18 and over diagnosed with epithelial ovarian 
cancer.  In these studies we used serum collected from 19 early stage and 95 late stage 
serous ovarian cancer patients prior to treatment or surgery.  The benign ovarian cyst 
group included 100 samples.  One hundred healthy controls were self-reported to be 
free of cancer and potentially confounding benign conditions such as ovarian cysts, 
uterine fibroids, or endometriosis. The HARS antigen was not processed with the 
Validation II sample set, with the exception of n=5 early stage HGSOC samples.  
Sample usage tracking ensured that the 314 samples selected for the two validation 






2.2. Sub-cloning of Antigens 
 The tumor antigens were first PCR amplified using forward primers (containing 
6X His tag and T7 tags) and reverse primers using cDNA template obtained from 
ovarian tumor samples or ovarian cancer cell lines SKOV3 or OVCAR3.  The PCR 
products were column purified, digested with restriction endonucleases and ligated to 
pET-21b bacterial expression vector (EMD Millipore Corporation, San Diego, CA) 
(Figure 2.1).  The ligated DNA was then transformed into the BL21-DE3 strain and 
positive colonies were selected; all cDNA expression plasmids used in this study were 
fully DNA sequenced. These expression vectors were employed for in vivo production of 
recombinant His-tagged proteins in Bl21-DE3 bacterial strain.  
2.3. Purification of Antigens 
 The BL21-DE3 bacterial cells bearing clones were grown overnight in 5 mL LB 
with 50 µg/mL ampicillin at 37° C. 0.5 mL of the overnight culture was added to 500 mL 
LB with 50 µg/mL ampicillin and grown at 37° C to OD between 0.4-0.5, IPTG (β-D-1-
thiogalactopyranoside) was added to a final concentration of 0.6 mM to induce the 
production of T7 RNA polymerase within the BL21-DE3 expression host, which is 
required for RNA and subsequent protein synthesis and the culture was grown at 37° C 
for three hours.  The cells were pelleted at 1,200 X g for 15 minutes and supernatant 
was discarded.  The pellet was frozen at -80°C for at least 30 minutes and then lysed 
with Thermo Scientific Bacterial Protein Extraction Reagent lysis buffer, centrifuged at 
15,000 X g and then transferred the supernatant.  The pellet, containing the target 





2.3.1. HIS-Tag Purification 
 The crude His-tagged proteins were purified first using Ni-NTA beads (Thermo 
Fisher Scientific, Waltham, MA) following manufacturer’s protocol.  Ni-NTA beads bind 
to His residues that are attached to proteins and results in relatively pure protein.  
Western blot image of elutions of His-Purification are shown in Figure 2.1; elutions were 
pooled and quantified with Bio-Rad DC protein assay. 
2.3.2. T7-Tag Purification 
 The Ni-NTA purified His-tagged proteins were further purified using T7•Tag® 
Antibody Agarose (MilliporeSigma, Burlington, MA) which bind the N-terminal 11 aa of 
the T7 gene 10 protein.  The second round of purification with T7 Antibody bound 
agarose beads is necessary to remove any contaminating bacterial poly-His containing 
proteins from first round of Ni-NTA bead purification.  Following purification, proteins 
were processed through Zeba desalting columns (Thermo Fisher Scientific, Waltham, 
MA).  Western blot image of elutions of T7-Purification are shown in Figure 2.1; elutions 
were pooled and quantified with Bio-Rad DC protein assay. 
2.3.3. Commercial Proteins 
 The recombinant proteins in this study are full-length, with the exception of the 
recombinant PAX8 protein that consists of the amino acids 1-287 (Sino Biological, 
Wayne, PA).  The SRP-19 expression plasmid was kindly gifted by Dr. Howard M. 
Fried, University of North Carolina at Chapel Hill [76].  The human TP53 (1-393) 
expression plasmid was a gift from Cheryl Arrowsmith (Addgene plasmid #24859; 










Figure 2.1:  Protein Purification Overview. 
A.  PET-21b vector map.  B.  Elutions of T712A antigen, His-column purification, anti-HIS 





2.4. Western Blot 
 Western blots were performed with 0.5 µg of purified recombinant proteins 
separated on a 10% acrylamide SDS-PAGE.  Proteins were transferred onto 
nitrocellulose membranes for one hour on ice at 250mA.  The membranes were blocked 
overnight at 4°C with 5% milk in TBS with 0.1% Tween20 (TBS-T).  The next day, each 
serum sample was pre-incubated at a 1:300 dilution in 3 ml of 5% milk in TBS-T with 75 
µg of BL21-DE3 E. coli lysate for one hour to reduce background reactions of human 
sera to E. coli proteins.  The patient serum was then incubated with nitrocellulose 
membranes for one hour at room temperature.  Following three washes with TBS-T, 
secondary IR-dye labeled mouse anti-His tag and goat anti-Human IgG antibodies were 
incubated for one hour at room temperature followed by three washes with TBS-T and 
two with PBS. Autoantibody binding to the antigens was quantified on LiCor Image 
Studio software (LI-COR Biosciences, Lincoln, NE) as background-corrected integrated 
intensity of anti-human IgG (IRDye800) normalized to anti-His tag antibody (IRDye700). 
Secondary anti-HIS tag antibody was quantified and used as a loading control to 
normalize each protein band to the anti-human IgG value.  The same lot of each 
secondary antibody was used for the experiment, and separate preparations of 
secondary antibody had no significant effect.  Day to day variation as calculated from 
the IRDye700 readings of the anti-His tag antibody was used to adjust data.  
2.5. ELISA 
2.5.1. Optimization of ELISA for Patient Serum Incubation 
 A semi-automated ELISA was developed using the Biomek3000 liquid pipetting 




substrate, and sulfuric acid.  Plates were coated with antigen with multichannel pipette 
by hand, and primary antibody consisting of patient serum diluted in blocking buffer was 
added with a single channel pipette by hand.  Optimization was performed for: 
concentration of coating antigen, dilution of patient samples, blocking reagent with  
patient samples, and timing of the washing procedure including plate drying times 
dependent on plate processing order. 
2.5.1.1. Selection of Blocking Agent 
 In order to optimize ELISA conditions, we processed plates with a number of 
blocking reagents.  The blocking reagents evaluated at various concentrations each 
included:  casein, gelatin, donkey serum (Jackson Laboratories), Donkey Serum 
(Equitech-Bio, Kerrville, TX), Aves Blocking buffer, Chonblock, Seablock, BSA, Milk, 
and keyhole limpet haemocyanin (KLH).  We found that the donkey serum from 
Equitech-Bio at 5% provided the lowest background.   
2.5.1.2. Serum Sample Preparation 
 Our primary antibody in this indirect ELISA was patient serum diluted 1:300.  
Originally, patient serum was diluted in washing buffer.  However we observed that a 
number of samples displayed reactivity with the various blocking agents used.  We 
found that pre-incubation of the patient samples in blocking reagent reduced this 
background.  Samples were incubated with blocking agent for one hour at room 
temperature with light rocking prior to addition to the ELISA plate, this incubation 
occurred simultaneously to the blocking agent on the ELISA plate.  Figure 2.2 shows 
the effects of pre-incubation of patient serum with blocking reagent: 5% Donkey Serum 











Figure 2.2:  ELISA: Sample Pre-Incubation with Donkey Serum. 
Pre-incubation of 10 patient samples for 1 hour at room temperature with blocking agent (5% 
donkey serum) reduced background reactivity.  Background is measured on non-coated wells 
with only PBS, blocked with donkey serum, and incubated with patient serum followed by 




















 In addition to pre-incubation of each patient sample in blocking reagent, we found 
that although proteins were doubly purified using the HIS and T7 tag, we found a few 
samples on western blot exhibited non-specific bands.  These bands were not 
associated with anti-His tag antibody signal on the IR700 channel,  and were detectable 
only on the IR800 channel.  On western blot, these non-specific bands were non-
consequential, as quantification was only measure on that IR800 band which 
overlapped with IR700 anti-His tag signal.  On ELISA however, these non-specific 
reactions create background noise.  Pre-adsorption of our patient sample with 75ug/mL 
of E. coli bacterial extract reduced non-specific bands observed on western blot as well 
as reduced optical density measurement on ELISA.   
2.5.1.3. ELISA Reproducibility 
 The serum set described in Table 4.1 was processed on ELISA. Each 
measurement was run in duplicate per plate, with four plates processed per day over 11 
days.  For 88 replicate measurements of the 1:75 dilution of the positive control 
standard curve, the coefficients of variation (CV) for the variance components in the 
ELISA assay are as follows:  Intra-assay CV (within plate) 0.0281; Inter-assay CV (plate 
to plate) 0.0749; and CV day-to-day 0.0898 [39].  Reproducibility within a single plate is 
shown in Figure 2.3.  
2.5.1.4. Antigen Concentration 
 Optimal antigen concentration was determined using positive control serum 
purchased from The Binding Site (San Diego, CA).  Various lots of these serum 
samples were positive for: CDR2, CDR2L, HARS, and TRIM21.  For those antigens that 











Figure 2.3:  ELISA Uniform Plate.    A.  OD values from uniform CDR2-coated ELISA 
plate with positive control patient serum as primary antibody.  B.  OD values from uniform 





concentrations of antigens with patient serum samples that were previously observed to 
react.  The concentration of antigen that provided half-maximum signal was selected as 
the working antigen concentration for subsequent studies.   
2.5.2. ELISA, Validation I 
 The serum set described in Table 4.1 was processed on ELISA as follows: 
purified antigens were coated in duplicate wells at concentrations from 0.3-1.5 mg/mL 
(depending on the protein as determine from preliminary tests) in PBS and incubated 
overnight at 4°C.  All subsequent steps took place at room temperature. Wells were 
blocked for one hour with 5% donkey serum in PBS.  To eliminate background of patient 
sera reactivity with donkey serum and a lysate of nonspecific bacterial proteins, 
samples were diluted 1:100 in PBS with 5% donkey serum and 75 mg of BL21-DE3 E. 
coli lysate for one hour.  Patient samples were incubated on the plate for one hour, 
followed by one-hour incubation of donkey anti-human HRP-conjugated secondary 
antibody.  TMB substrate solution (Thermo Fisher Scientific, Waltham, MA), containing 
3.3', 5.5'-tetramethylbenzidine (TMB) was added, followed by 0.45 M sulfuric acid to 
stop the reaction after 20 minutes.  The addition of blocking solution, washing steps, 
TMB and sulfuric acid addition were performed on the Biomek2000 automated liquid 
handling robot (Beckman Coulter, Brea, CA).   
 A standard curve using serum with known reactivity to TRIM21 (The Binding Site, 
San Diego CA) at five dilutions ranging from 1:75 to 1:1200 was included on each plate 
to account for plate-to-plate and day-to-day variation. In addition, a pair of non-coated 




patient serum specific background values were subtracted from the antigen values for 

























3. CHAPTER 3: Selection of Antigens by Detection of Paraneoplastic 
Autoantibodies in OVCA sera 
3.1.   Homology of OVCA Epitopes to Paraneoplastic Antigens 
3.1.1. Background: Phage-Display Biopanning 
 OVCA-related epitopes were previously identified by screening unbiased 
random-peptide phage display cDNA libraries using ovarian cancer sera and selectively 
enriching reactive epitopes through biopanning with ovarian cancer and healthy control 
samples [27, 30].  Using this high throughput epitope cloning strategy, the Tainsky 
laboratory identified 56 autoantibody biomarkers for ovarian cancer, three of which 
predicted recurrent ovarian cancer 9 months prior to clinical recurrence [27].  One of 
these three biomarkers is homologous to paraneoplastic antigen HARS, which is 
associated with paraneoplastic myositis [27].  Using NCBI Protein Blast for the 56 
sequences reactive with ovarian cancer patient serum, it was found that several 
epitopes shared amino acid sequence homology with paraneoplastic antigens [30].  
Two epitopes, 4B7 and 3A9, displayed 100% homology to the myositis associated 
antigens HARS and SRP-19, respectively [27, 30].  Additionally, four ovarian cancer 
epitopes, 4F10, 4E8, 5H6, and 5A3 and showed partial homology to the paraneoplastic 
antigens TRIM21, Hu-D, MUSK, and CDR2.  Alignments of the epitopes with the full-
length antigen amino acid sequence are shown in Figure 3.1 
3.1.2. OVCA epitopes incubated with paraneoplastic IgG on microarray 
 Commercially available positive control autoimmune serum samples were 
purchased from The Binding Site (San Diego, CA). Three control samples were utilized: 










Figure 3.1:  Homology of OVCA Epitopes to Paraneoplastic Antigens. 
Alignments from NCBI protein-BLAST search for OVCA epitopes with proteins associated 
with paraneoplastic syndromes.  Top sequence indicates OVCA epitope sequence; middle 






















Figure 3.2:  Autoimmune Patient Serum with OVCA IgG. 
A. Overview of positive control serum incubated with OVCA macroarrays. 





regarding the disease status of the donor patient was not available, these serum 
samples contained high titers of either anti-HARS antibodies, anti-CDR2 antibodies, or 
anti-HuD antibodies.  Autoimmune sera were processed with OVCA epitope 
macroarrays, with 4 phage clones displaying high reactivity (Figure 3.2:B), confirming 
reactivity with both ovarian cancer patient sera and autoimmune condition patient sera.  
The 4 reactive phage clones were amplified and purified from E. coli for evaluation on 
western blot.   
3.2. Paraneoplastic Line Blots 
 
 An initial survey of autoantibodies to 20 paraneoplastic antigens in HGSOC sera 
[29] [28] was performed, including the five antigens to which ovarian cancer epitopes 
showed homology; HARS, SRP-19, TRIM21, CDR2 and Hu-D (Figure 3.3).  This study 
utilized two commercially available line blots in which recombinant antigens were 
spotted onto a membrane, with one line blot test consisting of myositis-associated 
antigens, and a second line blot test consisting of onconeuronal antigens associated 
with paraneoplastic neurological syndrome. 
 Myositis-associated antigens were evaluated on line blots from Euroimmun 
(EUROIMMUN, Leubeck, Germany) and onconeuronal antigens associated with 
paraneoplastic syndromes were evaluated on line blots from Ravo Diagnostika (Ravo 
Diagnostika, Freiburg, Germany).  The antigens included on the Euroimmun myositis 
line blots are: TRIM21, OJ, EJ, PL-12, PL-7, SRP, HARS, PM-SCL75, PM-SCL100, KU, 
and MI-2.  The antigens included on Ravo Diagnostika paraneoplastic antigen line blots 











Figure 3.3:  Paraneoplastic Antigen Line Blots. 
Serum set of 34 HGSOC samples, 9 benign samples, and 11 healthy samples processed on 
Euroimmun and Ravo Diagnostika line blots, with 20 antigens total. 
A:  Image of Euroimmun myositis line blot and Ravo Diagnostika paraneoplastic antigen line 
blot with anti-HARS and anti-TRIM positive control serum and anti-CDR2 positive control 
serum, respectively. 
B:  Heat map of reactivity of line blots with HGSOC serum, as scored from 0-4. 
C:  Heat map of reactivity of line blots with benign serum, as scored from 0-4. 













line blots were processed per manufacturer protocol, incubated with a serum sample 
diluted at 1:100. 
3.2.1. Association of Western Blot results with Paraneoplastic Line Blots 
 
 There were ten samples processed on both the line blots and on western blot 
with the antigens HARS, CDR2, and TRIM21.  Results from each platform are shown in 
Table 3.1. 
3.3. Re-analysis of Recurrence Biomarker Study Data Set 
 We previously used phage-display screening to identify autoantibody biomarkers 
for both early detection and recurrence of ovarian cancer [27, 30].  Two of our identified 
markers were epitopes from myositis-associated antigens, HARS and SRP-19.  We 
note that in our previous work, the antigens CDR2, TRIM21, and HARS were evaluated 
for reactivity to antibodies in sera from patients experiencing a recurrence of their 
HGSOC; however, in that study the levels of autoantibody were considered relative to a 
negative control antigen for each individual patient at three time points, with the goal of 
monitoring disease recurrence [28].   
 With the goal of early detection in the current study, autoantibodies were 
considered relative to healthy and benign control serum samples.  We re-analyzed data 
from the recurrence study establishing a threshold using the healthy control samples 
within the sample set.  The western blot was quantified as described in section 2.4, with 
the anti-Human IgG intensity normalized to the anti-His tag loading control per antigen; 
the resulting values are plotted in Figure 3.4.  In the original data set, samples were 
taken from 3 time points for each patient, labeled as T1, T2, and T3.  For this analysis, 





Table 3.1:  Line Blot and Western Blot Association 
    
Reactivity of Antigen 
Biomarkers 
BSID Sample ID CA125 Test HARS TRIM21 CDR2 
674 P128-Cancer(R)-T2 13 
Western Blot 0.1  0.21 
Line Blot    
1740 P135-Cancer(R)-T2 11 
Western Blot  15.15 1.75 
Line Blot  3 4 
1681 P146-Cancer(R)-T2 25 
Western Blot 0.09 0.45  
Line Blot  1  
3905 P184-Cancer(R)-T2 5 
Western Blot   0.2 
Line Blot   2 
3776 P175-Cancer(R)-T2 18 
Western Blot  34.5 0.3 
Line Blot  4  
784 P25-Cancer(NR)-T2 12 
Western Blot 0.1   
Line Blot    
832 P164-Cancer(NR)-T2 28 
Western Blot    
Line Blot    
4012 P189-Cancer(NR)-T2 6 
Western Blot 0.07 1.93 0.29 
Line Blot  2 1 
4069 P206-Cancer(NR)-T2 7 
Western Blot    
Line Blot  1  
7428 P281-Cancer(NR)-T2 6 
Western Blot 0.06   
Line Blot 1 1  
 
Table 3.1:  Reactivity of 10 samples evaluated on line blot and western blot with TRIM21, 














Figure 3.4:  TRIM Reactivity and CA125.  A.  Western blot reactivity with TRIM21.  B.  





before treatment and most closely matches the serum samples used in our early 
detection studies.  10/31 (32%) HGSOC ovarian cancer cases were positive for TRIM21 
protein, with 0/21 healthy control samples, and 1/22 (0.05%) of samples from women 
with benign gynecological conditions, shown in Figure 3.4.  Figure 3.4:B shows 
samples that had CA125 values below clinical cutoff. 
3.4. Western blot and ELISA preliminary screening 
 
 Next, selected antigens were purified for further analysis on western blot and 
ELISA.  The following antigens were either expressed in E. coli and purified in house, or 
obtained commercially for quantitation in western blot and ELISA assays: SRP-19, 
HARS, AARS, CDR2, HuD, TRIM21, TRIM33, CDR2L, CORTACTIN, CKB, NY-ESO-1, 
PAX8 and TP53 (Table 3.2).  In addition, the four phage display epitopes with homology 
to paraneoplastic antigens were sub-cloned, expressed in E. coli and purified [27].  A 
representative western blot is shown in Figure 3.5.  Both the homologous epitopes and 
full-length protein pairs were evaluated; in all cases the full-length protein provided 
increased sensitivity.  Therefore the full-length protein was utilized in future studies 
rather than the purified epitope peptides.   
The serum set of n=36 samples is described in Table 3.3 and consisted of 12 
Healthy control samples, 12 samples representing benign gynecologic conditions 
including uterine fibroids, endometriosis, and ovarian cysts, and 12 late-stage HGSOC.  
Western blot was performed first with 11 antigens. HARS, TRIM21, CDR2, and P3F10 
had the lowest individual one-way ANOVA p-values.  Individual antigen reactivity is 
shown in a matrix plot in Figure 3.6.  Each purified antigen was incubated with patient 



























 HARS 4B7: Epitope Jo-1 
Myositis, 
Dermatomyositis OVCA, lung [180, 203] 





breast cancer [100, 185] 






 CORTACTIN  Anti-Cor Myositis  [102] 
 AlaRS  PL-12 Myositis Lung, gastric [180, 197] 










Breast, OVCA [52, 124] 




Breast, OVCA [52, 98] 










SCLC [93, 137] 
 P3F10  Anti-P3F10 
OVCA epitope that 
binds PNS sera OVCA [27] 
TAA TP53  Anti-TP53 
Systemic lupus 
erythematosus, 
Type I Diabetes, AI 
Thyroid Disease 
Pancreatic, 
Breast, OVCA [31, 91] 
 NY-ESO-1  Anti-NY-ESO-1 N/A, Cancer/Testis Antigen 
Lung, Breast, 
OVCA [175] 






Table 3.2:  Paraneoplastic antigens purified; the 8 antigens shaded in gray are those selected for 
the large-scale screening on western blot and ELISA.  Epitopes identified by phage-display 
screening of ovarian cancer (OVCA) serum [27].  PNS=Paraneoplastic Neurological Syndrome, 












Figure 3.5:  Western Blot Image, n=36. 
Purified antigens on western blot.  Blue boxes indicate full-length protein and corresponding 
homologous OVCA epitope pair.  A. anti-HIS tag antibody.  B. Patient serum and anti-




























Table 3.3:  Serum sample patient population (n=36), analyzed on western blot and 
ELISA, preliminary screening. 
 
 
Preliminary Screening Set 
          Patient Description Number of Samples 
           Age range 
(Avg)(Median) 
Late Stage HGSOC at time of 
diagnosis, pre-treatment 12 
44-47 
(57.4) (56.5) 
Benign gynecological condition 
(ovarian cyst, endometriosis, uterine fibroids) 12 
29-72 
(50.1) (50.5) 












































Figure 3.6:  Matrix Plot, n=36 
Ratio of IR800:IR700 value representing the anti-Human IgG antibody adjusted for protein 
loading with the anti-HIS tag antibody is plotted on the X and Y axes for each possible 
marker pair as labeled in the center diagonal gray boxes, with each patient sample represented 
as a single point.  Benign samples are labeled in blue, cancer samples are labled in red, and 
healthy samples are labled in green.  Red boxes represent the pairs which individually 












to 6X Histidine tag. Anti-human antibody intensity is normalized to antibody intensity for 
each his-tagged antigen.  As a visual representation of which marker pairs were 
compatible, each antigen pair was plotted against the other using a matrix plot in a log 
scale so that each patient could be represented by a single point defined by two 
markers, which are labeled as cancer, healthy, or benign in Figure 3.6.  Certain 
combinations separated the cancer category to the upper quadrant, so additive effects 
of marker pairs were then evaluated.  Combining the four markers HARS, P3F10, 
TRIM21, and CDR2 by taking the log of the product (equal to the sum of the four marker 
values on a log scale), the p-values using one-way ANOVA are: 4.9E-06 for Healthy vs. 
HGSOC and 1.2E-05 for Benign vs. HGSOC.   
 This set of 36 serum samples was also run on ELISA, 3 times, each time 
adjusting ELISA conditions.  Differences in antigen concentration are shown in Table 
3.4.  Additionally, the number of plates processed per day and the order in which they 
were processed varied between studies, as we found that variation in plate drying time 
between washing steps affected results as observed by an order-processed effect.  The 
ELISA procedure established in the third ELISA experiment with the n=36 sample set 
are the conditions utilized in the large-scale n=164 experiment as described in section 
2.5.2.   
 Results from western blot and ELISA screening with a serum set of n=36 
samples are shown in Table 3.4.  This set of 12, 12, 12 samples was also included in 
the study of recurrent ovarian cancer described in section 3.1, utilizing the T2 time 
points as described in section 3.2.  This represents western blot 2 as labeled WB2 in 






Table 3.4:  Results from Preliminary Screening of Purified Recombinant Proteins on 









Table 3.4:  Positive Samples from 3 ELISA and 2 western blot screening, performed with 
varying antigen concentrations as shown.  A set of 36 sera consisting of 12 healthy, 12 benign 
gynecological disease, and 12 high-grade serous ovarian cancer was run on three separate 
ELISA experiments, as well as twice on western blot.  Sensitivity is calculated relative to 
healthy and benign samples at 90% specificity.  With these six markers, a total of 10/12 
samples were positive using at least one assay.  Samples positive for each assay are shaded in 
















3.5. Description of Antigens Selected for Large-Scale Validation (n=164) 
 
 From the commercial line blot, western blot, and ELISA screenings, three 
myositis-associated antigens, three paraneoplastic cerebellar degeneration associated 
antigens, and three tumor-associated antigens were selected for validation on a large-
scale western blot and ELISA study using an independent sample set.  The 8 selected 
antigens are highlighted in Table 2.1. 
 
HARS, Histidyl-tRNA synthetase.   
 HARS catalyzes the transfer of Histidine to its cognate tRNA during protein 
synthesis, and HARS splice variants have reported immuno-modulatory roles [210].  
Antibodies against the HARS antigen are termed Jo-1 autoantibodies [193, 203].  Anti-
tRNA synthetase antibodies are common in myositis, with Jo-1 autoantibodies having 
the highest frequency [35].  
TRIM21, E3 ubiquitin-protein ligase TRIM21, Sjogren’s Syndrome type A antigen.   
 TRIM21 has E3-ligase activity as well as roles in intracellular pathogen clearance 
with a potent fc-receptor and activation of the innate immune response [121].  
Antibodies against TRIM21 are termed SSA-autoantibodies or Ro-52 autoantibodies 
and are associated with Sjogren’s syndrome, myositis, systemic lupus erythematosis, 
and systemic sclerosis [133, 134] .  
Cortactin, Src substrate cortactin.   
 Anti-cortactin autoantibodies were identified in sera of patients with polymyositis 
and in a separate study in myasthenia gravis who were sero-negative for classic 




immunohistochemistry and mRNA analysis of tumor tissues was reported to be 
associated with poor prognosis in ovarian cancer [108].  
CDR2, Cerebellar degeneration-related protein 2.   
 CDR2 interacts with c-myc and down-regulates c-myc dependent transcription in 
tumor cells, and is involved in mitotic cell division [130, 171].  Autoantibodies against the 
CDR2 antigen are termed Yo autoantibodies and are detected in patients with 
paraneoplastic cerebellar degeneration [46, 52].  
CDR2L, Cerebellar degeneration related protein 2-like.   
 CDR2L (CDR2-Like) shares 50% homology to CDR2; Yo autoantibodies can 
target both proteins. The function of CDR2L is unknown [52]. 
TP53, Cellular tumor antigen p53. 
 TP53 is a tumor suppressor and transcription factor involved in cell cycle 
regulation, DNA repair activation, apoptosis activation, and senescence.  Somatic 
mutations in p53 are found in approximately half of all human cancers, and in 96% of 
HGSOC cases [37]; autoantibodies to p53 in HGSOC can be detected against the wild 
type protein as a polyclonal response [91].  Autoantibodies to p53 are also detected in 
autoimmune conditions in which DNA antibodies are present, such as SLE, type I 
diabetes, and autoimmune thyroid disease [31]. 
NY-ESO-1, Cancer/testis antigen 1.   
 NY-ESO-1 is involved in cell growth and apoptosis. The restricted expression in 
testis suggests germ cell self-renewal function. Anti-NY-ESO-1 autoantibodies, 
originally identified by SEREX technology, have been detected in multiple tumor types 




target for ovarian cancer with numerous trials evaluating vaccines targeting NY-ESO-1 













































4. CHAPTER 4: Validation I: 14 Antigens Screened with n=164 Serum Sample Set 
on ELISA and Western Blot 
4.1. Patient Sample Population, n=164, Processed on ELISA and Western Blot 
 
 To avoid experimental bias, an independent sample set of 164 samples that had 
not been used to identify the biomarkers initially was used for validation of the antigens 
described in chapter 3.  The sample population consisting of 50 healthy control 
samples, 50 benign ovarian cyst samples, 50 late stage HGSOC samples, and 14 early 
stage HGSOC samples is described in Table 4.1, and will be referred to as the 
Validation I sample set.  
4.2. 12 Antigens Evaluated on ELISA or Western Blot with n=164 Sera 
4.2.1. Methods: ELISA 
4.2.1.1. Antigens 
The following 8 antigens were screened on ELISA: TRIM21, HARS, CDR2, 
CDR2L, NYESO1, TP53, and P3F10 using T712A as a negative control.  P3F10 was an 
epitope selected in chapter 3 based on elevated reactivity with sera from patients with 
paraneoplastic syndromes.  The empty phage control T712A was included as P3F10 
epitope includes a portion of this phage coat sequence.  The reactivity of P3F10 was 
determined by subtracting the T712A OD value from the P3F10 OD value.  TRIM21 and 
HARS are antigens associated with myositis/dermatomyositis, CDR2 and CDR2L are 
associated with paraneoplastic cerebellar degeneration, and TP53 and NY-ESO-1 are 
tumor-associated antigens previously demonstrated to react with autoantibodies in 





Table 4.1:  Serum Sample Patient Population (n=164), Analyzed on Western Blot and 




Validation Set I 
          Patient Description Number of Samples 
           Age range 
(Avg)(Median) 
Late Stage HGSOC at time of 
diagnosis, pre-treatment 50 
39-81* 
(62.6) (62) 
Early Stage HGSOC at time of 
diagnosis, pre-treatment 14 
44-76 
(58.8) (57) 
Benign gynecological condition 
(ovarian cyst) 50 
17-76 
(48.8) (49.5) 







Table 4.1:  Patient Population, n=164.  Serum samples analyzed on ELISA and western blot.  































 For the ELISA data analysis, to adjust for day-to-day variability among the 44 
ELISA plates measured across 11 days, we utilized the positive control measurements 
to construct the standard curve, which was measured on all plates. The linear curve 
consisted of 6 dilutions of a positive control serum sample (The Binding Site, San 
Diego, CA) measured against TRIM21 in duplicate, as shown in Figure 4.1.  A linear 
mixed model with log optical density (OD) as the response; dilution (treated as a factor), 
protein (either TRIM21 or BKG) and their interaction as the fixed effects; plate nested 
within day as a random effect; an estimated correlation structure between duplicate 
observations; and unequal variance within each protein/dilution combination. From this 
model, we extracted the random effects terms to adjust the observed log(OD) values. 
After averaging the duplicates and exponenting resultant value, the appropriate control 
adjusted OD was subtracted to produce the normalized OD measurement. This 
normalized OD measurement was then used to compare to the values from the western 
blot analysis. 
4.2.2. Methods: Western Blot 
4.2.2.1. Antigens 
  The following 10 antigens were evaluated on western blot:  TRIM21, HARS, 
CDR2, CORTACTIN, CDR2L, NYESO1, TP53, BRCA-1, CMYC, and PAX8.  TRIM21, 
HARS, and CORTACTIN are antigens associated with myositis/dermatomyositis, CDR2 
and CDR2L are associated with paraneoplastic cerebellar degeneration, and TP53, NY-
ESO-1, BRCA-1, CMYC, and PAX-8 are tumor-associated antigens previously 










Figure 4.1:  ELISA Standard Curve, Validation I, n=164 
The ELISA assay was run with a standard curve of 0.75 µg TRIM21 incubated with 5 
dilutions (1:1200, 1:600, 1:300, 1:150, 1:75) of the same positive control patient serum per 
plate.  This curve was used to adjust sample values for day-to-day variation.  Each color 
represents one day, each data point represents the average of two duplicate background-













expressed in HGSOC.  These 10 antigens were processed on two separate western 
blot studies; the first study included the 7 antigens TRIM21, HARS, CDR2, 
CORTACTIN, CDR2L, NYESO1, TP53, and the second study included the 3 antigens 
BRCA-1, CMYC, and PAX8.  Figure 4.2 shows the first set of 7 antigens on western 
blot with the Validation I sample set. 
4.2.2.2. Standardization 
 Quantification of autoantibody binding on western blot for each sample was 
measured over 15 days for Validation I for each of the 8 antigens, and measured over 
16 days for Validation II for 4 antigens, utilizing multiple membranes per day. Samples 
were randomized per category of HGSOC, benign, and healthy with each category 
evenly distributed per day, and labeled so that the experimenters were blinded to the 
sample category. The quantification values for both the IRDye700 and IRDye800 
channels were log transformed after the addition of a small constant (0.01) to ensure all 
values were positive. The difference between the log transformed IRDye700 and 
IRDye800 values for each antigen for each sample is the pre-adjustment analysis 
metric. We employed a mixed model to develop adjustment factors to account for the 
between-day variability. We utilized the estimated day-specific random effects (from a 
model including the log difference as the response, antigen as the fixed effect and day 
as the random effect) to account for day-to-day variability. The log difference minus the 
day-specific random effect was used as the final analysis metric.  Subsequently, for 
each antigen, the mean and standard deviation of the analysis metric was computed 
using the healthy samples.  This standardized value was used in the figures and tables 











Figure 4.2:  Western Blot Image, Validation I, n=164. 
Western blot of healthy control serum and early stage HGSOC serum diluted at 1:300 with 7 
antigens in Validation I study.  A) Secondary antibody anti-HIS tag IgG loading control.  B) 
Secondary antibody anti-human IgG.  Scans quantified on Odyssey software; background-
corrected integrated intensity of anti-human IgG antibody (IRDye800) normalized as ratio to 

























4.2.3.1. Individual Antigen Results: ELISA 
 
 Individual antigen reactivity is shown in Figure 4.3.  Positive control serum for 
HARS, TRIM21, and CDR2 as described in section 3.1.2 were also evaluated on 
ELISA.    
4.2.3.2. ELISA Saturated Signal 
 Samples that generated a saturated signal on ELISA were assigned a maximum 
OD value of 4 for analysis.  All samples with saturated signal were confirmed as positive 
on western blot (Figure 4.4). 
4.2.3.3. Individual Antigen Results: Western Blot 
 The ratio of anti-human IgG:anti-HIS IgG intensity values are plotted for each 
antigen for the late-stage HGSOC, early-stage HGSOC, benign ovarian cyst, and 
healthy control groups in Figure 4.5.  
4.2.3.4. ELISA and Western Blot Correlation 
 A threshold based on the 50 healthy control values for each antigen defined 
positive results.  The assay cutoff for both the ELISA assay and the western blot 
screening is defined as: Mean + 2(StdDev) for the healthy controls.  Using this criterion, 
NY-ESO-1, TP53, and TRIM21 had the highest sensivities and specificities on both 
platforms.  Among all HGSOC samples (n=64), 16/18 samples positive for NY-ESO-1 
on ELISA were confirmed by western blot, 14/16 TP53 samples positive on ELISA were 
confirmed by western blot and 11/13 TRIM21 samples positive on ELISA were 
confirmed by western blot.  However, for the marker TRIM21, 10 additional positive 









Figure 4.3:  ELISA Individual Antigen Graphs, Validation I, n=164.  Background-adjusted 
normalized optical density for each antigen.  H=healthy, M=mucinous cyst, S=serous cyst, 
E=early stage HGSOC, S3=stage 3 HGSOC, S4=stage 4 HGSOC, BX=positive control serum 












Figure 4.4:  Samples with ELISA Saturated Signals Confirmed on Western Blot. 
ELISA saturated signals for TP53 and TRIM21 confirmed as specific positive reactions on 
western blot.  IR800 anti-human IgG is shown in green, IR700 anti-HIS antibody is shown in 





















               
 
Figure 4.5:  Western Blot 
Individual Antigen Reactivity, 
Validation I, n=164. 
 
H=Healthy, M=Mucinous Cyst, 
S=Serous Cyst, E=Early stage 
HGSOC, S3=Stage 3 HGSOC, 













Figure 4.6:  Correlation of Western Blot and ELISA.  NY-ESO-1, TP53, and TRIM21 
western blot values correlated with ELISA values; each sample is represented as a single data 
point.  Red represents HGSOC cases, black indicates healthy or benign cases.  Samples in the 


























4.2.3.5. ELISA Treatment with Reducing Agent DTT 
 
 Prior studies have demonstrated enhanced detection of anti-TRIM21 antibodies 
on ELISA under reducing conditions, including samples with autoantibodies that were 
undetectable in non-reducing conditions [134, 141].  In Validation I, a threshold based 
on the 50 healthy control values for each antigen defined positive results. Seven of the 
positive samples that were identified on western blot but were not detected by ELISA 
were processed again on ELISA using TRIM21-coated plates that were treated with 
DTT.  Results are shown in  Table 4.2; treatment with DTT did not affect ELISA 
reactivity.  A representative image of a sample positive for TRIM21 on western blot that 
was undetectable by ELISA is shown in Figure 4.7.  Additionally, the marker HARS did 
not react on ELISA whereas it showed reactivity on western blot.  HARS was treated 
with DTT, and did not show any improvement in ELSA detection for 2 samples that were 
positive on western blot. 
Lack of reactivity can be due to protein binding to the plate and resulting epitope 
availability on ELISA, as well as increased background noise in the ELISA platform that 
can interfere with detection of a positive signal.  A number of patient samples retained 
an inherent high background on ELISA regardless of pre-incubation of the serum 
sample with blocking agent (5% donkey serum) and bacterial extract as described in 
Methods.  It was concluded that western blot eliminates ambiguities introduced by 
samples with high background noise and is the more reliable platform for detection of 






Table 4.2  ELISA Results: TRIM21 + DTT 
 


















TRIM21 Sample 1 O47 WB + ELISA - 0.409 0.369 0.041 
TRIM21 Sample 2 O40 WB + ELISA - 0.254 0.275 -0.022 
TRIM21 Sample 3 O12 WB + ELISA - 0.209 0.216 -0.007 
TRIM21 Sample 4 O46 WB + ELISA - 0.305 0.211 0.094 
TRIM21 Sample 5 O33 WB + ELISA - 0.134 0.127 0.007 
TRIM21 Sample 6 O3 WB + ELISA - 0.012 -0.014 0.026 
TRIM21 Sample 7 O37 WB + ELISA + 1.940 1.956 -0.017 
TRIM21 Sample 8 O38 WB - ELISA - 0.042 0.067 -0.025 
TRIM21 Sample 9 O42 WB - ELISA - -0.014 -0.05 0.036 
 
Table 4.2:  Treatment with reducing agent DTT on ELISA.  OVCA samples positive on WB 































Figure 4.7:  Western Blot of Late-Stage HGSOC Sample Positive for TRIM21,  
Validation I. 
Late-Stage HGSOC sample positive for TRIM21 (800:700 standardized ratio > 2) on western 
blot, which was not detected by ELISA (Standardized background-corrected intensity <2).  
A) Secondary antibody anti-HIS tag IgG loading control.  B) Secondary antibody anti-human 




















4.2.3.6. Sensitivity/Specificity: TRIM21 provides highest sensitivity as 
an individual marker in HGSOC samples. 
 
 Sensitivities and specificities as calculated by the standardized thresholds based 
on mean + 2(StdDev) of the healthy controls and mean + 3(StdDev) of the healthy 
controls per antigen are reported in Table 4.3.  The resulting thresholds were applied to 
all patient groups: healthy, benign, early stage HGSOC, and late stage HGSOC. 
Applying the assay threshold=2 for western blot to TRIM21 yields 21 positive samples 
out of 64 HGSOC cases, including both early and late stage.  Notably, with 33% 
sensitivity TRIM21 did not positively react with healthy control samples.  Four benign 
ovarian cyst samples had reactivity above the healthy control threshold.  Individual 
sensitivities and specificities of all markers are shown in Table 4.3; the previously 
established biomarkers NY-ESO-1 and TP53 each detected 16/64 (25%) of HGSOC 
cases.  One healthy control sample with high reactivity to TP53 had self-reported family 
history of ovarian cancer. 
 Cortactin (COR), a novel biomarker for myositis, did not show HGSOC specificity 
[102].  We found that CDR2 and CDR2L had reactivity with healthy and benign 
samples.  Antibodies to CDR2 have previously been reported to have low frequency in 
ovarian cancer.  We observed 5/50 late stage and 2/14 early stage samples positive for 
CDR2 autoantibodies at the threshold (2)=Mean + 2(StdDev) [124].  Previous studies 
have shown that Yo-antibody positive patients with paraneoplastic cerebellar 
degeneration have anti-Yo antibodies that react with both CDR2 and CDR2L [52].  In a 
study evaluating ovarian cancer sera, anti-Yo positive sera reacted with CDR2L alone, 
or both CDR2 and CDR2L [52].  In our cohort, the three samples that were positive for 



























Antigen	 Sensitivity	 Sensitivity	 Sensitivity	 Specificity	 Specificity	 Specificity	
TRIM21	 0.34	 0.29	 0.33	 0.90	 1.00	 0.95	
TP53	 0.28	 0.14	 0.25	 0.98	 0.96	 0.97	
NYESO1	 0.24	 0.29	 0.25	 0.98	 0.98	 0.98	
HARS	 0.06	 0.29	 0.11	 0.90	 0.98	 0.94	
CDR2L	 0.06	 0.14	 0.08	 0.94	 0.96	 0.95	
CDR2	 0.10	 0.14	 0.11	 0.88	 0.96	 0.92	
COR	 0.02	 0.00	 0.02	 1.00	 0.96	 0.98	























Antigen	 Sensitivity	 Sensitivity	 Sensitivity	 Specificity	 Specificity	 Specificity	
TRIM21	 0.28	 0.21	 0.27	 0.92	 1.00	 0.96	
TP53	 0.26	 0.14	 0.23	 1.00	 0.98	 0.99	
NYESO1	 0.22	 0.29	 0.23	 1.00	 1.00	 1.00	
HARS	 0.02	 0.21	 0.06	 0.98	 1.00	 0.99	
CDR2L	 0.02	 0.14	 0.05	 0.96	 1.00	 0.98	
CDR2	 0.06	 0.14	 0.08	 0.94	 0.98	 0.96	
COR	 0.02	 0.00	 0.02	 1.00	 0.96	 0.98	
TRIM21,	TP53,	NYESO1	 0.58	 0.36	 0.53	 0.94	 0.98	 0.96	
 
Table 4.3: Sensitivity and specificity for TRIM21, TP53, NY-ESO-1, HARS, CDR2L, 
CDR2, and COR evaluated on western blot with n=164 sample set.  Threshold (2)=Mean + 













Table 4.4 CDR2 and CDR2L Combined Reactivity, n=164, Validation I  
 












CDR2>2 6 2 7 2 5 
CDR2L>2 3 2 4 1 3 
CDR2>2 + 
CDR2L>2 0 0 3 1 2 
 












CDR2>2 6 2 7 2 5 
CDR2L>1.5 6 3 6 2 4 
CDR2>2 + 
CDR2L>1.5 0 0 4 2 2 
 
 
Table 4.4: CDR2 and CDR2L, n=164, Validation I.  Samples positive for both CDR2 and 
CDR2L were all HGSOC cases.  Thresholds of 1.5 or 2 shown for individual antigens or the 



















In cases of myositis, patients that had the combination of TRIM21 and HARS were 
more likely to have cancer [115, 149].  In our cohort we observed 3/64 HGSOC patients 
with a combination of HARS and TRIM21 positive values. 
4.3. Additional Ovarian Cancer Tumor-Associated Antigens screened with 
n=164 sample set on western blot: BRCA1, CMYC, PAX8 
 
4.3.1. Study Design 
 
Three additional tumor-associated antigens were evaluated with the Validation I sample 
set: BRCA1, CMYC, and PAX8. 
4.3.1.1. Antigen Description 
 
C-myc, C-myc protein. 
 In a study by Wang et. al evaluating 12 tumor-associated antigens to identify 
ovarian cancer biomarkers, C-myc was identified as a top candidate biomarker as 
measured by ELISA.  C-myc was detected in 24/132 (18.2%) of ovarian cancer serum 
samples, and 3/147 (2%) of healthy control samples, with the positive cutoff defined as 
mean + 2 standard deviations of the healthy control samples [186]. 
BRCA1, Breast cancer type I susceptibility protein.  
 Autoantibodies to BRCA1 were detected in 17/34 ovarian cancer samples on 
ELISA [211].  BRCA1 and BRCA2 mutations account for the majority of hereditary 
breast and ovarian cancer cases [136]. 
PAX8, Paired box protein Pax-8.  
 Overexpression of PAX8 is associated with HGSOC [20, 189].  The present 
study is the first to detect anti-PAX8 autoantibodies.  The full-length PAX8 protein is 450 
aa; the recombinant PAX8 protein used in this study consists of the amino acids 1-287, 






 Western blot image of patient serum with the three antigens CMYC, BRCA1, and 
PAX8 is shown in Figure 4.8.  Individual antigen reactivity is shown in Figure 4.9.  Of 
the three markers, PAX8 demonstrated potential to complement NY-ESO-1, TP53, and 
TRIM21.  Alone, PAX8 was positive for 7/64 HGSOC samples, 5 of which were not 
detected previously.  Although previously reported to be elevated in HGSOC patient 
serum, both BRCA1 and CMYC reacted with HGSOC, healthy control, and benign 
ovarian cyst samples on western blot (Figure 4.9) [186, 211]. 
4.4. Analysis of 10 antigens Screened with n=164 Sera on Western Blot 
Identifies Top Panel of 4 Antigens: TRIM21, NY-ESO-1, TP53, and PAX8  
4.4.1. Panel of 4 Antigens: TRIM21, NY-ESO-1, TP53, and PAX8 provides 
highest sensitivity and specificity. 
 The combination of the four markers TRIM21, NY-ESO-1, TP53, and PAX8 
detected 42/64 HGSOC samples.  With 94% specificity for the healthy control 
population, we can achieve 67% sensitivity (threshold=2) for the 4-marker model. At 
98% specificity relative to the healthy control population, this 4-marker combination 
achieves 56% sensitivity (threshold=3). The maximum value among the 4 markers: 
TRIM21, NY-ESO-1, TP53, and PAX8 for each sample group is plotted in Figure 4.10.  
Table 4.5 shows performance of the combinations of these 4 markers.  ROC Curve 















Figure 4.8:  Western Blot Images, n=164, Validation I, Additional Tumor-Associated 
Antigens.  BRCA1, PAX8, and CMYC proteins with anti-HIS tag antibody shown on left 
panel.  Healthy, HGSOC, and Benign patient samples with anti-Human IgG antibody shown 
on right panel.  Reactivity of BRCA1 and CMYC is observed in Healthy and Benign 




































Figure 4.9:  Western Blot Individual Antigen Reactivity, n=164, Validation I, Additional 
Tumor-Associated Antigens.   H=Healthy, B=Benign, E=Early Stage HGSOC, O=Late 



















Figure 4.10:  Western Blot Individual Antigen Reactivity, 4 Antigens, Validation I, 
n=164. 
A-D) Individual antigen plots for 4 antigens, TRIM21, NY-ESO-1, TP53, and PAX8 in 
Validation I.  E) Maximum value of TRIM21, NY-ESO-1, TP53, or PAX8 in Validation I.  
The immunoreactivity as defined by the ratio of 800/700 is standardized for each antigen to 
provide the threshold of Mean + 2(StdDev) for healthy controls, as indicated by the 






















          
 
Figure 4.11:  ROC Curve Analysis, Validation I, n=164. 
ROC curve analysis for the combination of the 4 markers: TRIM21, NY-ESO-1, TP53, and 





4.4.2. TRIM21, HARS, NY-ESO-1, PAX8, and TP53 detected in early stage 
HGSOC samples. 
 
 The Validation I sample set included 14 early stage samples.  Individually, NY-
ESO-1 and HARS detected 4 early-stage HGSOC samples (29%), TRIM21 detected 3 
early-stage HGSOC samples (21%), and TP53 and PAX8 each detected 2 early-stage 
HGSOC samples (14%).  The combination of the 5 markers yielded 50% sensitivity for 
detecting early stage HGSOC with 94% specificity to discriminate healthy controls. 
Sensitivities and specificities within each sample group are shown in Table 4.5.  The 
combination of markers PAX8, HARS, NY-ESO-1, TP53 and TRIM21 detected 7/14 
early-stage HGSOC samples. Among these five antigens, all 7/7 of the positive early 
stage HGSOC samples were reactive with 2 or more antigens, compared with 12/37 






























Antigen	 Sensitivity	 Sensitivity	 Sensitivity	 Specificity	 Specificity	 Specificity	
TRIM21	 0.34	 0.29	 0.33	 0.90	 1.00	 0.95	
TP53	 0.28	 0.14	 0.25	 0.98	 0.96	 0.97	
NYESO1	 0.24	 0.29	 0.25	 0.98	 0.98	 0.98	
PAX8	 0.10	 0.14	 0.11	 0.96	 1.00	 0.98	
TRIM21,	TP53,	NYESO1	 0.64	 0.43	 0.59	 0.86	 0.94	 0.90	
TRIM21,	TP53,	























Antigen	 Sensitivity	 Sensitivity	 Sensitivity	 Specificity	 Specificity	 Specificity	
TRIM21	 0.28	 0.21	 0.27	 0.92	 1.00	 0.96	
TP53	 0.26	 0.14	 0.23	 1.00	 0.98	 0.99	
NYESO1	 0.22	 0.29	 0.23	 1.00	 1.00	 1	
PAX8	 0.04	 0.00	 0.03	 0.96	 1.00	 0.98	
TRIM21,	TP53,	NYESO1	 0.58	 0.36	 0.53	 0.94	 0.98	 0.96	
TRIM21,	TP53,	
NYESO1,	PAX8	 0.62	 0.36	 0.56	 0.88	 0.98	 0.93	
 
Table 4.5: Sensitivity and specificity for TRIM21, NY-ESO-1, TP53, and PAX8 evaluated 
on western blot with n=164 sample set.  Threshold (2)=Mean + 2(StdDev) for healthy 















5. CHAPTER 5: Validation II: Study of 4 Antigens on western blot 
 A separate serum set consisting of 50 healthy, 50 benign ovarian cyst, and 50 
high-grade serous ovarian cancer samples was used for an independent validation of 
the 4 markers: TRIM21, NY-ESO-1, TP53, and PAX8.  This sample set will be referred 
to as Validation II. 
5.1.1. Patient population, n=150 
 The patient population is described in Table 5.1.   
5.1.2. Antigens 
 Antigens were selected based on performance in Validation I for detection of 
HGSOC autoantibodies.  The four markers TRIM21, NY-ESO-1, TP53, and PAX8 
achieved the greatest AUC relative to healthy control samples in Validation I. 
5.2. Results 
5.2.1. Individual Antigen Results 
 Patient samples were evaluated with the panel of 4 markers: TRIM21, NY-ESO-
1, TP53, and PAX8 on western blot (Figure 5.1).  In this sample set, PAX8 did not 
complement the 3 markers TRIM21, NY-ESO-1, and TP53.  Standardized patient 
reactivity for each antigen is shown in Figure 5.2.  This validation screening of the 3 
markers TRIM21, NY-ESO-1, and TP53 maintained a specificity of 98% with a 
sensitivity of 46% as described in Table 5.2.    
5.2.2. Comparison to Validation I Study 
 The sensitivity of the combination of the 4 markers: TRIM21, NY-ESO-1, TP53, 
and PAX8 for all HGSOC cases was lower in the second validation study, 50% vs. 67% 










Validation Set II 
         Patient Description Number of Samples 
        Age range 
          (Avg)(Median) 
Late Stage HGSOC at time of 
diagnosis, pre-treatment 45 
37-87 
(63.6) (64) 
Early Stage HGSOC at time of 
diagnosis, pre-treatment 5 
43-66 
(51.6) (47) 
Benign gynecological condition 
(ovarian cyst) 50 
25-88* 
(56.5) (55) 







Table 5.1:  Patient population, n=150.  Serum samples analyzed on western blot.  *Indicates 

































Figure 5.1:  Western Blot Images, Validation II, n=150. 
Western blot of healthy control serum and early stage HGSOC serum diluted at 1:300 with 4 
antigens in Validation II study.  A) Secondary antibody anti-HIS tag IgG loading control.  B) 
Secondary antibody anti-human IgG.  Scans quantified on Odyssey software; background-
corrected integrated intensity of anti-human IgG antibody (IRDye800) normalized as ratio to 





























Figure 5.2:  Western Blot Individual Antigen Reactivity, 4 Antigens, Validation II, 
n=150. 
A-D) Individual antigen plots for 4 antigens, TRIM21, NY-ESO-1, TP53, and PAX8 in 
Validation II.  E) Maximum value of TRIM21, NY-ESO-1, TP53, or PAX8 in Validation II.  
The immunoreactivity as defined by the ratio of 800/700 is standardized for each antigen to 
provide the threshold of Mean + 2(StdDev) for healthy controls, as indicated by the 












































Antigen	 Sensitivity	 Sensitivity	 Sensitivity	 Specificity	 Specificity	 Specificity	
TRIM21	 0.38	 0.20	 0.36	 0.90	 0.96	 0.93	
TP53	 0.16	 0.00	 0.14	 0.96	 0.96	 0.96	
NYESO1	 0.20	 0.00	 0.18	 0.94	 1.00	 0.97	
PAX8	 0.09	 0.00	 0.08	 0.98	 0.96	 0.97	
TRIM21,	TP53,	NYESO1	 0.51	 0.20	 0.48	 0.80	 0.92	 0.86	
TRIM21,	TP53,	























Antigen	 Sensitivity	 Sensitivity	 Sensitivity	 Specificity	 Specificity	 Specificity	
TRIM21	 0.24	 0.20	 0.24	 0.98	 1.00	 0.99	
TP53	 0.16	 0.00	 0.14	 1.00	 0.98	 0.99	
NYESO1	 0.20	 0.00	 0.18	 0.98	 1.00	 0.99	
PAX8	 0.04	 0.00	 0.04	 0.98	 1.00	 0.99	
TRIM21,	TP53,	NYESO1	 0.49	 0.20	 0.46	 0.96	 0.98	 0.97	
TRIM21,	TP53,	




Table 5.2: Sensitivity and specificity for TRIM21, NY-ESO-1, TP53, PAX8, evaluated on 
western blot with n=150 sample set.  Threshold (2)=Mean + 2(StdDev) for healthy controls, 










not statistically significant at the 0.05 level (p-value=0.096 and p-value=0.369, 
respectively, using a 2X2 chi-square contingency table with Yates correction).   
Receiver Operating Characteristic (ROC) analysis resulted in area under the curve 
(AUC) of 0.832 for Validation I and 0.701 for Validation II (Figure 5.3).  For both sample 
sets, TRIM21 individually provided the highest AUC: 0.671 in Validation I and 0.618 in 
Validation II.  
5.2.3. Reactivity in Early Stage HGSOC Samples 
 Although the HARS antigen was not evaluated on this entire n=150 sample set, 
the 5 early stage HGSOC samples were processed with the HARS protein resulting in 
1/5 positive samples.  TRIM21 was the only other antigen positive in the 5 early stage 
HGSOC samples; combining TRIM21 and HARS resulted in 2/5 early stage HGSOC 
samples positive in this set.   
5.2.4. Low Grade Serous Ovarian Cancer Samples 
 As low-grade serous ovarian cancer (LGSOC) can develop step-wise from 
ovarian serous cystadenoma, it is a possibility that autoantibody positivity in the benign 
cyst samples may indicate preneoplastic lesions [181, 187].  We evaluated 22 samples 
from patients with early stage LGSOC with the antigens TRIM21, NY-ESO-1, TP53, 
PAX8, and HARS.  1/22 early stage LGSOC samples were positive for TP53 
autoantibodies and 1/22 samples were positive for TRIM21 autoantibodies.  LGSOC 
has a distinct protein expression and mutational profile from HGSOC however, and our 










            
 
Figure 5.3:  ROC Curve Analysis, Validation II, n=150. 
ROC curve analysis for the combination of the 4 markers: TRIM21, NY-ESO-1, TP53, and 





5.2.5. Stage Distributions Validation I and Validation II 
 Stage distributions for the two samples populations are shown in. Table 5.3.  
Although Validation I set had a higher number of stage 4 cases than the Validation set, 
within Validation I, Stage 3 sensitivity is 72% compared with sensitivity among stage 4 























Table 5.3:  Antigen Reactivity by Tumor Stage for HGSOC samples. 
 
Validation I, n=64            




















Positive 3 1 3 1 2 22 1 3 3 4 
Total 
samples 4 1 9 1 3 31 1 3 5 6 
% 0.75 1.00 0.33 1.00 0.67 0.71 1.00 1.00 0.60 0.67 
           
 TOTAL       
Stage  Stage 1 Stage 3  Stage 4 Stage 3 or 4 
All 
Stages      
# 
Positive 7 26 10 36 43      
Total 
samples 14 36 14 50 64      
% 0.50 0.72 0.71 0.72 0.67      
           Validation II, n=50         













NOS    
# 
Positive 0 1 0 22 0 1 1    
Total 
samples 3 2 1 36 2 4 2    
% 0.00 0.50 0.00 0.61 0.00 0.25 0.50    
             TOTAL       







Stages     
# 
Positive 1 22 1 1 24 25     
Total 
samples 5 39 4 2 45 50     
% 0.20 0.56 0.25 0.50 0.53 0.50      
NOS=Not otherwise specified         
 







6. CHAPTER 6: TRIM21 AUTOANTIBODIES IN HGSOC 
 
6.1. Summary of TRIM21 Reactivity with HGSOC Sera 
 
 TRIM21 consistently showed superior reactivity in multiple patient sample 
populations, including on line blots in section 1.1, on western blot and ELISA with a set 
of n=36 samples in section 3.2, and on western blot in Validation I in section 5.2 and in 
Validation II in section 6.2. TRIM21 was identified as a novel biomarker for ovarian 
cancer, with the highest individual sensitivity of 33% for all HGSOC samples at 100% 
specificity compared to healthy controls in Validation I, and 36% sensitivity at 96% 
specificity in Validation II.   
6.2. TRIM21 Function as Intracellular Pathogen Sensor and Potent Fc Receptor 
  
 TRIM21 consists of 4 domains: a RING domain involved in ubiquitination, B-box 
domain, coiled-coiled domain, and a c-terminal PRY-SPRY domain which is an 
immunoglobulin Fc receptor [94].  TRIM21 is the most potent mammalian Fc receptor.  
The PRY-SPRY domain alone binds with ~200 nM affinity, but when it binds as a dimer 
to the immunoglobulin heavy chain, the affinity is sub-nanomolar, at approximately 0.6 
nM [94].  There are 68 members in the TRIM protein family, however only TRIM21 has 
Fc binding ability [22].  This Fc binding function allows TRIM21 to neutralize antibody-
bound virus or bacteria.  Binding of TRIM21 to an antibody-bound pathogen initiates 
innate immune signaling as a multi-step process.  It neutralizes the virus by targeting for 
degradation and detection by RIG1 or cGAS, and activates NFKB and TLR signaling 
[49].   
The recent discovery that TRIM21 participates in neutralization of intracellular 




for therapeutics.  One group has demonstrated the ability of TRIM21 to disrupt tau 
aggregation using anti-tau antibodies, with potential for therapeutics for 
neurodegenerative diseases with protein aggregates [120].  Another technology has 
been proposed for degradation of endogenous proteins has been engineered around 
TRIM21 neutralization and is named the Trim-Away approach, which targets any protein 
by introduction of the target-specific antibody and over-expression of TRIM21 [120]. 
Autoantibodies are targeted to the Fc-binding domain [22].  It has been proposed 
that autoantibodies can be generated against TRIM21 when it is in complex with 
antibody-bound pathogens. Burbelo et al. have generated mutant TRIM21 proteins that 
are deficient in Fc-binding function, and demonstrated specific autoantibody binding to 
these mutants [22].  Additionally, TRIM21 positive serum was blocked with TRIM21 and 
other TRIM protein family members to demonstrate specific binding.  The Fc binding 
function of TRIM21 is conformation dependent; our studies utilized denatured protein.  
Studies with native TRIM21 demonstrated a low level of background signal present in all 
sample types, yet still observed specific TRIM21 autoantibodies in positive control sera 
with reactivity that was significantly elevated compared with controls [22]. We have 
demonstrated specific antibody binding by blocking a TRIM21 autoantibody positive 
control serum sample (The Binding Site, San Diego, CA) with TRIM21 antigen, shown in 
Figure 6.1. 
6.3. Screening for TRIM21 Autoantibodies in Samples from Patients with Pelvic 
Inflammatory Disease and other Benign Gynecologic Conditions. 
 
 To determine if TRIM21 autoantibodies can be detected in the setting of pelvic 











Figure 6.1:  Western Blot Evaluating TRIM21 Autoantibody Binding Specificity  
Positive control patient serum, sample ID:BX104 (The Binding Site, San Diego, CA) was 
pre-incubated with purified antigen prior to incubation on western blot.  Without pre-
incubation with antigen, BX104 reacts with HARS and TRIM21, and does not react with 
T712A on western blot.  Pre-incubation of BX104 with HARS specifically reduces reactivity 
with HARS, pre-incubation of BX104 with TRIM21 specifically reduces reactivity with 
TRIM21, and pre-incubation of BX-104 with T712A has no effect on HARS or TRIM21 on 


















reported pelvic inflammatory disease  (PID).   Patients with PID have bacterial or viral 
infection of the pelvis.  None of the 12 samples displayed reactivity with TRIM21 on 
western blot (Figure 6.2).  TRIM21 was detected in 5/50 benign ovarian cyst samples in 
Validation I and 5/50 ovarian cyst samples in Validation II. 
6.4. TRIM21 Reactivity in Ovarian Cancer Serum Samples 
 
 In a study of HGSOC serum samples that utilized high-density programmable 
protein microarrays containing 10,247 antigens, TRIM21 was identified as one of the top 
39 candidate tumor antigens, which passed three rounds of serum screening in 
independent sample sets [92].  From the top 39 candidate antigens, the authors 
selected a final panel of 11 antigens, which did not include TRIM21.  Performance of 
TRIM21 relative to the top 39 antigens is shown in Table 6.1.  TRIM21 has equal or 
greater performance than several antigens included in the final panel of 11 antigens.  
These studies were performed on a rapid ELISA platform, and in our experiments 
TRIM21 was undetectable o ELISA in 10 HGSOC serum samples that reacted with 
TRIM21 on western blot.   
6.5. TRIM21 Autoantibodies in Other Cancer Types 
 
 TRIM21 has previously been reported as a biomarker for esophageal squamous 
cell carcinoma (ESCC) and basal-like breast cancer [100, 185].  To identify 
autoantibody biomarkers for ESCC, a SEREX library created with cDNA from an ESCC 
cell line and screened with ESCC sera.  TRIM21 was identified from the SEREX 
screening and reactivity with patient serum was confirmed on ELISA and western blot 
[100].  TRIM21 autoantibodies were also detected in colon, gastric, and breast cancer 




selected in a set of 71 candidate autoantibody biomarkers for basal like breast cancer 
[185].  After 3 rounds of ELISA screening with basal like breast cancer sera, TRIM21 























Figure 6.2:  Western Blot: 12 PID Serum samples with TRIM21 and T712A. Positive 
control BX sera (The Binding Site, LLC), positive for TRIM21 and HARS is shown in the 
last column, with two HARS antigens, HARS1 (Novus Biologicals) and HARS2 (purified in 
lab), as well as the TRIM21 antigen which was included on PID samples 1-12.  Negative 
control antigen T712A was included on each membrane incubated with patient serum.  Serum 























Table 6.1  TRIM21 Reactivity on Rapid ELISA 
 
A. 
Healthy Threshold (Mean + 2 Std. Dev) 
per Antigen B. 
Benign Threshold (Mean + 2 Std. Dev) 
per Antigen 
 












NUDT11 8 1 1  NUDT11 8 1 2 
 
STYXL1 7 2 0  TRIM39 7 1 4 
 
PVR (B) 6 2 0  STYXL1 4 2 0 
 
CA4 5 2 0  PVR (B) 4 1 0 
 
POMC 5 4 1  KSR1 4 3 3 
 
UHMK1 4 4 0  CA4 3 2 0 
 
TRIM21 3 3 0  NY-ESO-1 3 2 0 
 
NY-ESO-1 3 4 1  TRIM21 2 1 0 
 
TP53 2 1 1  P53 2 1 0 
 
NXF3 2 4 0  POMC 2 1 0 
 
ICAM3 1 0 1  ICAM3 1 0 1 
 
TRIM39 1 0 1  UHMK1 1 2 0 
 
SAP18 3 2 1  NXF3 1 2 0 
 
TNFRSF11B 3 2 0  TNFRSF11B 2 1 0 
 
AKT1 3 3 1  KCNH2 1 2 2 
 
BRD3 3 1 2  CHRM4 1 1 3 
 
PRMT5 2 2 0  MAP3K7 1 1 1 
 
MLH1 2 0 1  PVR-A 1 1 2 
 
TUBB 1 3 1  TIMP3 1 1 2 
 
KCNH2 1 0 2  SAP18 1 2 0 
 
CHRM4 1 1 2  PRMT5 1 2 0 
 
LRRFIP1 1 1 1  NDUFA3 1 1 2 
 
WSB1 1 2 2  AKT1 1 1 1 
 
ELOVL2 1 0 2  MIB2 4 1 5 
 
AARS 1 2 1  BRD3 3 1 3 
 
MIB2 1 0 2  NPTX2 3 3 3 
 
KSR1 0 0 1  MLH1 3 2 4  
 
Table 6.1:  Analysis of Supplemental Data from: Katchman BA, Chowell D, Wallstrom G, et 
al. Autoantibody biomarkers for the detection of serous ovarian cancer. Gynecol Oncol. 
2017;146(1):129–136.  Thresholds calculated using values from A) healthy controls and B) 
benign samples.  Of the top 39 antigens selected from original 10,247 antigens, shown are 
those Positive count indicates sample value > threshold.  Antigens highlighted in yellow 
indicated final panel of 11 antigens selected by authors.  TRIM21 highlighted in turquoise, 





7. CHAPTER 7: Discussion 
 
7.1. Ovarian Cancer Early Detection Biomarker Performance 
 
 Early detection of ovarian cancer has the potential to improve patient outcome, 
as late stage disease is associated with widespread metastasis, complication of 
surgery, and drastically reduced prognosis.  Screening for ovarian cancer is currently 
not recommended for the general population, and there are no approved tests or 
markers for early diagnosis.  One method which has been evaluated in clinical trials is 
ROCA, which consists of a two-step test that involves measurement of circulating 
antigen CA125 at an increased level relative to each patient’s baseline interpreted with 
patient age, followed by imaging such as TVUS.  Having a sequential test process of 
orthogonal measurements reduces the rate of false-positives.  However, the initial step 
of CA125 detection in this two-step process misses approximately 20% of all cases as 
20% of all ovarian cancers do not shed CA125 [166].  Moreover, 40-50% of early stage 
cases with low-volume disease do not shed CA125 at levels high enough to be detected 
[194].    Autoantibodies to tumor antigens, produced at small tumor volumes, can be 
combined with serum screening of CA125 to improve sensitivity in early detection.  
TP53 autoantibodies have been detected in 16% of cases that were not detectable with 
CA125 in preclinical samples [194].  We have found that NY-ESO-1 and TRIM21 
autoantibodies are present in a higher percentage of early stage samples than 
autoantibodies to TP53.   
7.1.1. PPV Calculations 
 
 The positive and negative predictive values were estimated using a range of 




population level risk (1/2500).  We combined values from Validation I and Validation II 
for analysis of n=214 HGSOC cases and n=100 healthy cases for the three markers 
TRIM21, TP53, and NY-ESO-1, resulting in a sensitivity of 52% with a specificity of 
98%.  For a 10-fold increase in prevalence of OVCA (0.4%) relative to population 
prevalence, using a sensitivity of 52% and a specificity of 98%, we estimated the PPV 
and NPV.  PPV at 10, 15, or 20-fold increased prevalence was 9.4%, 13.5%, and 
17.2%, respectively, with NPV 99.8%, 99.6%, and 99.7%.  Additionally, in practice, 
these biomarkers would be combined with CA125 values presumably resulting in 
increased sensitivity, followed by TVUS, which would result in increased specificity.  
These results indicate that the panel could be useful for screening in a high-risk 
population, including BRCA1/2 mutation carriers and women with a family history of 
OVCA. 
7.1.2. High-risk population 
 
 In three recent studies within the population of women with an increased risk of 
ovarian cancer that evaluated CA125 using the ROCA method at intervals of 3 or 4 
months, an increase in detection sensitivity for early stage tumors was observed [147, 
166].   The goal of identifying autoantibody biomarkers is both to complement CA125, 
and to provide lead-time to CA125 detection.  The serum set used in this study had 
limited samples with data for CA125 values. Autoantibodies to TP53 have been shown 
by Yang et al. to be elevated in pre-diagnostic patient samples up to 11 months before 
detection of CA125, and in samples taken 23 months before diagnosis of ovarian 
cancer for cases that were not detected by CA125 [194].  In our cohort anti-TP53 




ESO-1, and PAX8, detected 9/19 additional early stage samples.  Addition of these 
markers to TP53 improves sensitivity, and may improve lead-time, thus addressing the 
ultimate goal of a diagnosis at an earlier stage.  Determining whether TRIM21, HARS, 
NY-ESO-1, and PAX8 autoantibodies are also detectable in addition to TP53 in pre-
diagnostic sera will be a critical step in evaluating these biomarkers for clinical use.  
Early detection of HGSOC has potential to provide a mortality reduction  [86]. 
7.2. Autoantibodies as predictors of neurologic irAEs 
 
 In addition to early detection, this work also describes the frequency of 
paraneoplastic antibodies in HGSOC patients without a neurological syndrome.  In lung 
cancer, the frequency of the anti-Hu antibody has been reported to be 16-25% in 
patients without a syndrome [93].  Assessing the frequency of autoantibodies in cancers 
associated with paraneoplastic syndromes can contribute to understanding the etiology 
of paraneoplastic syndromes.   
 With increasing success of immunotherapy for cancer treatment, determining if 
patients can be stratified into those likely develop a paraneoplastic syndrome as a result 
of immunotherapy will be critical for optimal patient care.  Baseline levels of 
autoantibodies have been assessed for their utility to predict risk of neurologic irAEs 
with immune-checkpoint therapy [10].  As described in section 1.2.3., immunotherapy 
strategies are being developed for ovarian cancer including CAR-T cell, vaccines, 
CTLA-4 and PD-1-inhibiton in combination with Parp-inhibition.  Although markers such 
as CDR2 and CDR2L did not provide early detection diagnostic ability, they may serve 




may be at risk of developing neurologic irAEs, particularly paraneoplastic cerebellar 
degeneration. 
7.3. Conformational Considerations 
 The antigens used in this study were purified form E. coli and were denatured 
with both urea and heat.  These methods limit the ability to detect antibodies against 
conformation-dependent epitopes.  Production of protein in E. coli results in lack of 
posttranslational modifications and proper folding as observed in human cells [88].  
Additionally, treatment with heat and urea results in unfolded protein.  Follow up studies 
to determine if native protein will detect additional cases are warranted.  Antibody-
antigen binding is also limited due to solid surface immobilization of our antigen, which 
can restrict epitope availability [13].  Due to variability in performance between antibody 
detection platforms, confirmation of positive results on a separate platform may be 
necessary [172]. 
 Additionally, autoantibodies can be in complex with antigen has been described 
for ovarian cancer biomarkers HE-4 and CA125 [40, 195].  In the case of CA125, 
presence of CA125 immune complexes were associated with decreased antigen 
concentration, presumably due to assay interference [40].  Whether antigen-
autoantibody complexes hamper autoantibody detection can be assessed with pre-
treatment of samples to dissociate complexes. 
7.4. Sources for Novel Autoantigen Discovery 
 Rather than screening serum against protein libraries, novel methods of antibody 
discovery aim at directly sequencing the autoantibody content from serum samples.  




results have been shown to not accurately represent circulating IgG [21].  
Supplementing with protein-level data is necessary to identify relevant antibodies [34].  
One approach involves top-down mass spectrometry analysis of intact immunoglobulins 
purified from serum.  IgG can also be digested and the Fab-fragment which binds 
antigen is then sequenced, with bottom-up data analysis with alignment of sequences to 
a reference library.  Top-down and bottom-up approaches can be integrated for a more 
complete analysis of the antibody repertoire in a single sample [48] 
Sources of antibody discovery include samples from patients that were sero-
negative for existing biomarkers.  This approach has been used for discovery of novel 
paraneoplastic autoantibodies that were common among samples sero-negative for the 
classical markers [102, 174].  Within our Validation I and Validation II sample sets, the 
HGSOC samples that did not react with our panel of 4 antigens could be pooled as a 
discovery sample resource.   
The precursor of the majority of high-grade serous ovarian cancers is widely 
recognized as serous tubal intraepithelial carcinoma.  These lesions have been 
identified in the fallopian tubes of patients who underwent RRSO.  Gene expression 
profiling has identified HGSOC signatures to better correlate with normal fallopian tube 
than ovarian surface epithelium [50].  Tissue from resected serous tubal intraepithelial 
carcinoma are excellent sources for biomarker discovery as they represent the earliest 
phases of tumor progression which have been reported to be present years prior to 






8. CHAPTER 8:  Conclusions and Future Directions 
 
 The goal of this dissertation work was to evaluate the serum autoantibody levels 
to paraneoplastic antigens in HGSOC in order to identify candidate biomarkers for early 
detection.  A panel of autoantibody biomarkers can be useful in complementing current 
screening methods for the early detection of ovarian cancer in women with an increased 
genetic risk of ovarian cancer.  Our laboratory has previously identified epitopes 
reactive with ovarian cancer patient serum using phage-display technology.  As 
described in Chapter 3, we identified phage-borne epitopes that were homologous to 
antigens associated with paraneoplastic neurological syndromes.  In Chapter 3, the 
presence of paraneoplastic antibodies in HGSOC sera was evaluated.  We screened a 
panel of 20 paraneoplastic antigens against patient serum samples and identified 
candidate antigens reactive with HGSOC sera: TRIM21, HARS, AlaRS, SRP, CDR2, 
and HuD.  We further sub-cloned full-length HIS-tagged protein of these markers as well 
as 4 epitopes with homology to HARS, TRIM21, SRP, and HuD.  These proteins were 
purified from E. coli using HIS tag and T7 tag, and evaluated on western blot and ELISA.  
In Chapter 4, we performed a screening of n=164 patient samples against 9 selected 
antigens on western blot and ELISA:  TRIM21, HARS, CDR2, CDR2L, CORTACTIN, 
NY-ESO-1, TP53, P3F10, and T712A.  Autoantibodies against the HARS antigen were 
more frequently detected in early stage sera than in late stage sera, and autoantibodies 
against TRIM21 were observed at the highest frequency.  An additional 3 tumor-
associated antigens were processed with the n=164 sample set: BRCA1, CMYC, and 
PAX8.  We determined that the combination of 4 markers: TRIM21, NY-ESO-1, TP53, 




panel of 4 markers on an independent serum set consisting of n=150 patient serum 
samples on western blot.  In this study, the combination of TRIM-21, NY-ESO-1, TP53, 
and PAX8 provided a sensitivity of 46% with 98% specificity.  
This study is the first to demonstrate accuracy of TRIM21 autoantibodies as a 
biomarker for HGSOC in a large-scale screening.  TRIM21 was previously identified as 
a relevant tumor-associated antigen in basal-like breast cancer, ESCC, and serous 
ovarian cancer through proteomics-based discovery.  In Validation I and Validation II, 
autoantibodies to TRIM21 were detected at 33% and 36% sensitivity in all HGSOC 
cases with 100% and 96% specificity compared to healthy controls.  Somatic mutations 
in TP53 are found in in 96% of HGSOC cases [37]; autoantibodies to TP53 in HGSOC 
can be detected against the wild type protein as a polyclonal response [91].  NY-ESO-1 
is an immunotherapy target for ovarian cancer with numerous trials evaluating vaccines 
targeting NY-ESO-1 as well as adoptive transfer of NY-ESO-1 specific T-cells [131].  
PAX8 is expressed in the majority of HGSOCs [20].  The present study is the first to 
detect anti-PAX8 autoantibodies.  
 These studies provide evidence that autoantibodies associated with 
paraneoplastic syndromes can be identified in the serum of patients diagnosed with 
cancer who do not present with paraneoplastic symptoms.  We found that although a 
number of paraneoplastic antibodies are present in HGSOC sera, the anti-TRIM21 
antibodies provided the best sensitivity and specificity for use in early detection.  
Combination of TRIM21 with established tumor antigens NY-ESO-1 and TP53 
enhanced sensitivity and specificity.  Furthermore, we demonstrated that anti-PAX8 




 The identified autoantibody biomarkers should be validated with pre-diagnostic 
serum samples to determine the time prior to diagnosis that the autoantibodies can be 
detected.  Another area for further study is to expand the current panel by identification 
of autoantibodies in those serum samples that did not react with our set of 4 markers.  
Additionally, assessment of these markers in companion with CA125 will be performed 
with the Validation I and Validation II sample sets, which is essential for determination of 
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The majority of ovarian cancer cases are diagnosed at an advanced stage 
metastatic disease with poor prognosis due to non-specific symptoms and lack of early 
detection methods.  This study evaluates autoantibodies against tumor antigens to 
identify candidate biomarkers for the early detection of ovarian cancer in high-risk 
women.  We examined antigens associated with paraneoplastic neurological synromes, 
which are autoimmune diseases that develop when the unregulated immune response 
against a tumor also targets healthy cells.  Notably, a set of autoantibodies have been 
previously detected in paraneoplastic neurological syndrome patients with concurrent or 
subsequent diagnosis of ovarian cancer, identifying highly immunogenic antigens in the 
tumor. 
In this dissertation work, we have detected paraneoplastic antibodies present in 
serum samples from patients with high-grade serous ovarian cancer (HGSOC) without 
paraneoplastic neurological syndromes using line blots, western blots, and ELISA.   A 
panel of five paraneoplastic antigens (HARS, TRIM21, COR, CDR2, CDR2L) along with 




on western blot and ELISA.  Screening was performed with a patient serum set 
consisting of: 50 late stage HGSOC, 14 early stage HGSOC, 50 benign ovarian cyst, 
and 50 healthy volunteer samples.  On western blot, the paraneoplastic antigen with the 
best performance was TRIM21 with 35% sensitivity.  Combining TRIM21 with p53 and 
NY-ESO-1 yielded a sensitivity of 60% with 90% specificity.  In the early stage HGSOC 
sample set, HARS demonstrated 31% sensitivity individually, and 46% sensitivity with 
98% specificity when combined with p53 and NY-ESO-1.  The identified markers will 
were tested in an independent validation serum set consisting of n=150 samples.   The 
work in this dissertation identified the paraneoplastic antigen TRIM21 that can enhance 
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